2-oxo-1,2-dihydrobenzo[cd]indole compound and use thereof

The present invention relates to the technical field of medicinal chemistry, and in particular discloses a 2-oxo-1,2-dihydrobenzo[cd]indole compound and use thereof. The compound and pharmaceutically acceptable salt, isomer, racemate, prodrug, co-crystallized complex, hydrate, and solvate thereof can effectively inhibit the BET bromodomain receptor, and can be used for preparing a medicine for treating cancers, cell proliferative disorders, inflammatory diseases, and autoimmune disorders, sepsis, and viral infections.

1-10. (canceled)

11. A 2-oxo-1,2-dihydrobenzo[cd]indole compound having a structure represented by formula I, II, III or IV:

wherein, R₁ is selected from H or C₁-C₄ linear or branched alkyl,

R₂ is selected from C₁-C₇ alkyl, C₁-C₄ alkylene-R₆, C₁-C₄ alkylene-R₇-cyclic ring, —R₇-cyclic ring or -cyclic ring,

R₃ is selected from C₁-C₇ alkyl, C₁-C₄ alkylene-R_6′, C₁-C₄ alkylene-R₇-cyclic ring, —R₇-cyclic ring or -cyclic ring,

R₄ is selected from C₁-C₇ alkyl, C₁-C₄ alkylene-R_6″, C₁-C₄ alkylene-R₇-cyclic ring, —R₇-cyclic ring or -cyclic ring,

R₅ is selected from C₁-C₇ alkyl, C₁-C₄ alkylene-R_6″, C₁-C₄ alkylene-R₇-cyclic ring, —R₇-cyclic ring or -cyclic ring,

wherein R₆ is selected from —OR₈, —COR₈, —CONHR₈, —COOR₈, —S(O)_mR₈, —NHCOOR₈, —NHCOR₈ or —NH₂, wherein m is 0 or 2,

R_6′ is selected from —OR₈, —COR₈, —CONHR₈, —COOR₈ or —S(O)_mR₈, wherein m is 0 or 2,

R_6″ is selected from —OR₈, —COR₈, —CONHR₈, —COOR₈, —S(O)_mR₈, —NHCOOR₈ or —NHCOR₈, wherein m is 0 or 2,

R₈ is selected from hydrogen or C₁-C₃ alkyl, and

R₇ is selected from —COR₉, —COOR₉ or —OR₉, wherein R₉ is selected from C₁-C₃ alkylene, wherein cyclic ring is selected from C₃-C₁₀ cycloalkyl, phenyl, or heterocyclic group, or a pharmaceutically acceptable salt, isomer, racemate, prodrug, cocyrstalline complex, hydrate or solvate thereof.

12. The compound according to claim 11, wherein R₁ is selected from H, methyl, ethyl, propyl, isopropyl or tert-butyl.

13. The compound according to claim 11, wherein

the cyclic ring is selected from cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, phenyl, naphthyl, azetidine, oxetane, azacyclopentane, oxacyclopentane, azacyclohexane, oxacyclohexane, azacyclohexyl, imidazol-2-one ring, imidazolyl, furyl, thienyl, oxazolyl, isoxazolyl, pyrimidinyl, pyrrolyl, piperazinyl, tetrahydropyrrolyl, piperidinyl, morpholinyl, 1,3-dioxolanyl or benzo[d]thiazolyl, wherein the cyclic ring is substituted by 0, 1, 2 or 3 group(s) each independently selected from halogen, methyl, ethyl, propyl, isopropyl, tert-butyl, trifluoromethyl, cyano, nitro, amino, amide, —COOR₁₀, —COR₁₀, —OR₁₀, —NHCOR₁₀, —NHCOOR₁₀, —C₆H₅R₁₁, morpholinyl, piperidinyl, tetrahydrofuranyl or pyridyl, wherein R₁₀ is selected from hydrogen, C₁-C₄ alkyl or phenyl, and R₁₁ is selected from C₁-C₄ alkyl, halogen, acetyl, methoxy or ethoxy.

14. The compound according to claim 11, wherein the compound is selected from a group consisting of:

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)butane-1-sulfonamide;

2-chloro-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-4-fluorobenzenesulfonamide;

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)thiophene-2-sulfonamide;

5-chloro-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-2-methoxybenzenesulfonamide;

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)cyclohexanesulfonamide;

2-(N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)sulfamoyl)benzoate;

2-(N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)sulfamoyl)benzoic acid;

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)benzenesulfonamide;

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-4-fluorobenzenesulfonamide;

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-3-fluorobenzenesulfonamide;

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)ethanesulfonamide;

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-4-methoxybenzenesulfonamide;

4-cyano-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)benzenesulfonamide;

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-4-nitrobenzenesulfonamide;

4-(tert-butyl)-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)benzenesulfonamide;

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-4-(trifluoromethoxy)benzenesulfonamide;

3-chloro-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-2-fluorobenzenesulfonamide;

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-4-methylbenzenesulfonamide;

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-2,4-difluorobenzenesulfonamide;

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)propane-1-sulfonamide;

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)cyclopentanesulfonamide;

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-4-(trifluoromethyl)benzenesulfonamide;

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-3-(methylsulfonyl)benzenesulfonamide;

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)naphthalene-2-sulfonamide;

4-(N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)sulfamoyl)benzoate;

4-(N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)sulfamoyl)benzoic acid;

3-(N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)sulfamoyl)benzoate;

3-(N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)sulfamoyl)benzoic acid;

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-2,3-dihydrobenzo[b][1,4]dioxine-6-sulfonamide;

2-bromo-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)benzenesulfonamide;

5-bromo-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-2-methoxybenzenesulfonamide;

2,6-dichloro-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)benzenesulfonamide;

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-2,3-dimethoxybenzenesulfonamide;

3,5-dichloro-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)benzenesulfonamide;

2,3-dichloro-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)benzenesulfonamide;

4-((N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)sulfamoyl)methyl)benzoate;

4-((N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)sulfamoyl)methyl)benzoic acid;

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-1-(3-fluorophenyl)methanesulfonamide;

3-((N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)sulfamoyl)methyl)benzoate;

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-1-(4-(trifluoromethyl)phenyl) methanesulfonamide;

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-1-(p-tolyl)methanesulfonamide;

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-1-(2-fluorophenyl)methanesulfonamide;

1-(4-chlorophenyl)-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)methanesulfonamide;

1-(4-cyanophenyl)-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)methanesulfonamide;

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-1-(4-fluorophenyl)methanesulfonamide;

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-4-fluorobenzamide;

2-(4-chlorophenyl)-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)acetamide;

2-(3,4-dimethoxyphenyl)-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)acetamide;

2-(2,4-dichlorophenyl)-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)acetamide;

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-3-phenylpropanamide;

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-4,4,4-trifluorobutanamide;

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)propionamide;

4-chloro-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)benzamide;

N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-2-(p-tolyl)acetamide;

(E)-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-3-(furan-2-yl)acrylamide;

1-ethyl-6-((3-phenylpropyl)amino)benzo[cd]indol-2(1H)-one;

1-ethyl-6-((3-morpholinopropyl)amino)benzo[cd]indol-2(1H)-one;

1-ethyl-6-((4-methoxybenzyl)amino)benzo[cd]indol-2(1H)-one;

1-ethyl-6-((4-methylbenzyl)amino)benzo[cd]indol-2(1H)-one;

1-ethyl-6-((4-(trifluoromethyl)benzyl)amino)benzo[cd]indol-2(1H)-one;

6-((4-chlorobenzyl)amino)-1-ethylbenzo[cd]indol-2(1H)-one;

1-ethyl-6-((4-fluorobenzyl)amino)benzo[cd]indol-2(1H)-one;

N-((1-acetylpiperidin-4-yl)methyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

1-((1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole)-6-sulfonamido)cyclohexane-1-carboxamide;

1-ethyl-N-((3-isopropyl-4,5-dihydroisoxazol-5-yl)methyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

N-((3,5-dimethyl-4,5-dihydroisoxazol-5-yl)methyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

N-(4-acetylphenyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

N-(2-chlorobenzyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

1-ethyl-N-(2-fluorobenzyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

N-(1-acetylpiperidin-4-yl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

Tert-butyl4-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)piperidine-1-carboxylate;

N-cyclopentyl-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

Ethyl1-((1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)methyl)cyclopentanecarboxylate;

1-((1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)methyl)cyclopentanecarboxylic acid;

N-(4-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)phenyl)acetamide;

2-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)benzoic acid;

1-ethyl-N-(4-fluorophenyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

N-butyl-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

N-(2-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)ethyl)acetamide;

1-ethyl-N-(2-(methylsulfonyl)ethyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

1-ethyl-2-oxo-N-(2-(2-oxoimidazolidin-1-yl)ethyl)-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

Tert-butyl(4-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)butyl)carbamate;

N-(5-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)pyridin-2-yl)acetamide;

Tert-butyl3-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)pyrrolidine-1-carboxylate;

Tert-butyl3-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)azetidine-1-carboxylate;

N-(2-cyclohexylethyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

1-ethyl-2-oxo-N-(pyrrolidin-3-yl)-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

N-(azetidin-3-yl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

1-ethyl-N-hexyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

1-ethyl-2-oxo-N-(2-(pyrrolidin-1-yl)ethyl)-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

1-ethyl-2-oxo-N-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

1-ethyl-2-oxo-N-(tetrahydrofuran-3-yl)-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

N-(2-(4-chlorophenoxy)ethyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

N,1-diethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

1-ethyl-2-oxo-n-pentyl-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

1-ethyl-N-methyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

N-cyclohexyl-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

Tert-butyl3-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)piperidine-1-carboxylate;

1-ethyl-N-isobutyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

1-ethyl-2-oxo-N-propyl-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

1-ethyl-N-(3-(4-methylpiperazin-1-yl)propyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

1-ethyl-2-oxo-N-(2-(piperidin-1-yl)ethyl)-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

N-(4,4-diethoxybutyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

Ethyl 3-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)propanoate;

1-ethyl-N-((1-ethylpyrrolidin-2-yl)methyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

1-ethyl-N-(1-methylpiperidin-4-yl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

N-cycloheptyl-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

1-ethyl-2-oxo-N-(tetrahydro-2H-pyran-4-yl)-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

Tert-butyl4-(2-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)ethyl)piperazine-1-carboxylate;

N-cyclohexyl-1-methyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

N-butyl-1-methyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

N-cyclohexyl-2-oxo-1-propyl-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

2-oxo-N,1-dipropyl-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

N-butyl-2-oxo-1-propyl-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

N-butyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

N-butyl-1-isobutyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

N-cyclohexyl-1-isobutyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

N-cyclohexyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

N-(3-acetylphenyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

N-(4-chlorophenyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

1-ethyl-2-oxo-N-phenyl-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

N-(2-chlorophenyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide; and

N-(3-chlorophenyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide.

15. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 11 and a pharmaceutically acceptable carrier.

16. A method of inhibiting a BET bromodomain receptor in a subject in need thereof, comprising: administering to the subject a therapeutically effective amount of the compound according to claim 11.

17. A method for treating a disease or a condition selected from the group consisting of cancers, cell proliferative disorders, inflammatory diseases, and autoimmune disorders, sepsis, and viral infections, in a subject in need thereof, comprising: administering to the subject a therapeutically effective amount of the compound according to claim 11.

18. The method according to claim 17, wherein the cancers comprise: adrenal tumor, acoustic neuroma, acral lentiginous melanoma, acrospiroma, acute eosinophilic leukemia, acute erythroid leukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, acute monocytic leukemia, actue promyelocytic leukemia, adenocarcinoma, adenoid cystic carcinoma, adipose tissue tumor, adrenocortical carcinoma, adult T-cell leukemia/lymphoma, AIDS-related lymphoma, alveolar rhabdomyosarcoma, alveolar soft part sarcoma, ameloblastic fibroma, anaplastic large cell lymphoma, anaplastic thyroid cancer, angiomyolipoma, angiosarcoma, astrocytoma, atypical teratoid rhabdoid tumor, B-cell chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, B-cell lymphoma, basal cell carcinoma, biliary tract cancer, bladder cancer, blastoma, bone tumor, brown tumor, Burkitt's lymphoma, breast cancer, brain cancer, carcinoma in situ, chondroma, cementoma, myeloid sarcoma, chondroma, chordoma, choriocarcinoma, choroid plexus papilloma, clear-cell sarcoma of the kidney, craniopharyngioma, cutaneous T-cell lymphoma, cervical cancer, colon cancer, small round cell tumor, diffuse large B-cell lymphoma, neuroepithelial tumor, dysgerminoma, embryonal carcinoma, endocrine gland neoplasm, endodermal sinus tumor, esophageal cancer, fibroma, fibrosarcoma, follicular lymphoma, follicular ganglioneuroma, thyroid cancer, gastrointestinal cancer, germ cell tumor, gestational choriocarcinoma, giant cell fibroblastoma, giant cell tumor of the bone, neurogliocytoma, glioblastoma multiforme, glioma, granulosa cell tumor, andreoblastoma, gallbladder cancer, gastric cancer, hemangioblastoma, head and neck cancer, hemangiopericytoma, hepatoblastoma, cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, invasive lobular carcinoma, intestinal cancer, kidney cancer, laryngeal cancer, lethal midline carcinoma, leukemia, leydig cell tumor, liposarcoma, lung cancer, lymphangioma, lymphoepithelioma, lymphoma, acute lymphangiosarcoma, lymphoblastic leukemia, chronic lymphocytic leukemia, liver cancer, small cell lung cancer, non-small cell lung cancer, MALT lymphoma, malignant fibrous histiocytoma, malignant peripheral nerve sheath tumor, marginal zone B-cell lymphoma, mast cell leukemia, mediastinal germ cell tumor, medullary carcinoma of the breast, medullary thyroid cancer, medulloblastoma, melanoma, meningioma, merkel cell cancer, mesothelioma, metastatic cell carcinoma, mixed Mullerian tumor, mucinous tumor, multiple myeloma, muscle tissue neoplasm, mycosis fungoides, myxoid liposarcoma, myxoma, myxosarcoma, nasopharyngeal carcinoma, neuroblastoma, neurofibroma, neuroma, ocular cancer, oncocytoma, optic nerve sheath meningioma, tumor, oral cancer, osteosarcoma, ovarian cancer, papillary thyroid cancer, tumor paraganglioma, pinealoblastoma, pituicytoma, precursor T-lymphoblastic lymphoma, primary central nervous system lymphoma, peritoneal cancer, prostate cancer, pancreatic cancer, pharyngeal cancer, renal cell carcinoma, renal medullary carcinoma, retinoblastoma, rhabdomyoma, rhabdomyosarcoma, rectal cancer, sarcoma, seminoma, Sertoli cell tumor, skin cancer, small round cell tumor, small cell carcinoma, soft tissue sarcoma, somatostatinoma, spinal tumor, splenic marginal zone lymphoma, squamous cell carcinoma, synovial sarcoma, small intestine cancer, squamous carcinoma, stomach cancer, T-cell lymphoma, testicular cancer, thyroid cancer, transitional cell carcinoma, throat cancer, urachal cancer, urogenital cancer, uterine cancer, verrucous carcinoma, visual pathway glioma, vulvar cancer, and vaginal cancer.

19. The method according to claim 17, wherein the cell proliferative disorders comprise: benign soft tissue tumor, brain and spinal tumor, eyelid and orbital tumor, granuloma, lipoma, meningioma, multiple endocrine neoplasia, nasal polyp, pituitary tumor, prolactinoma, seborrheic keratose, stomach polyp, thyroid nodule, liver hemangioma, vocal cord nodule, polyp, cyst, pilonidal disease, dermatofibroma, pilar cyst, and pyogenic granuloma.

20. The method according to claim 17, wherein the inflammatory diseases comprise: inflammatory pelvic disease, urethritis, skin sunburn, nasosinusitis, pneumonitis, encephalitis, meningitis, myocarditis, nephritis, osteomyelitis, myositis, hepatitis, gastritis, enteritis, dermatitis, gingivitis, pancreatitis, psoriasis, allergy, Crohn's disease, bowel syndrome, ulcerative colitis, rejection of transplanted tissues, rejection of transplanted organs, asthma, allergic rhinitis, chronic obstructive pulmonary disease, autoimmune disease, autoimmune alopecia, anemia, glomerulonephritis, dermatomyositis, multiple sclerosis, scleroderma, vasculitis, autoimmune hemolytic and thrombocytopenic states, Goodpasture's syndrome, athersclerosis, Addison's disease, Parkinson's disease, Alzheimer's disease, diabetes, septic shock, systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, chronic idiopathic thrombocytopenic purpura, myasthenia gravis, Hashimoto's thyroiditis, atopic dermatitis, degenerative joint disease, Guillain-Barre syndrome, mycosis fungoides, and acute inflammatory responses.

21. The method according to claim 17, wherein the viral infections comprise: human papillomavirus, Herpesvirus, Epstein-Barr virus, human immunodeficiency virus, hepatis B virus, and hepatitis C virus infections.

The present invention relates to the technical field of chemical medicines, and specifically to a 2-oxo-1,2-dihydrobenzo[cd]indole compound and use thereof.

The bromodomain (BRD) family of proteins recognizes and binds to the acetylated lysine acting as a reader of lysine acetylation state. These “epigenetic readers” bind to acetyllysine residues on the tails of histones H3 and H4, and regulate chromatin structure and gene expression. There is increasing evidence of their role in human disease, and recently a number of small-molecule nihibitors have been reported. There is increasing evidence for the roles of BRDs in disease including inflammation, neurological indications, viral infection, cancers, and autoimmune disorder.

An analysis of the human proteome has revealed that there are eight distinct BRD families, representing 61 different BRDs from 46 separate proteins, although others may still be undiscovered. The BET family of BRDs is a subset of this larger bromodomain family and is made up of four members: BRD2, BRD3, BRD4, and BRDT in humans. BRD2 and BRD3 are reported to associate with histones along activity transcribed genes and may be involved in facilitating transcriptional elongation, while BRD4 appears to be involved in the recruitment of the P-TEFb complex to inducible genes, resulting in phosphorylation of RNApolymerase and increased transcription output. Chromosomal translocation of BRD3 and BRD4 to the nuclear protein in testis (NUT) locus generates BRD3-NUT or BRD4-NUT fusion protein that results in c-Myc overexpression and NUT midline carcinoma (NMC), an aggressive squamous cell malignancy unresponsive to conventional chemotherapeutics. BRDT is uniquely expressed in the testes and ovary.

Recently, a number of small-molecule compounds with potent inhibitory activity against BET family proteins have been reported. The first potent BET inhibitor was the diazepine JQ1 by nuclear magnetic resonance technology, subsequently, more molecues were reported by epigenetic screening and targeted biochemistry. By these potent inhibitors, more knowledge about the relationship of BET proteins and diseases was disclosed. Rapid progress in the development of bromodomain ligands has stimulated extensive interest and has led to several BET bromodomain inhibitors reaching clinical trials for cancers and inflammations.

The technical problem to be solved by the present invention is: providing a 2-oxo-1,2-dihydrobenzo[cd]indole compound, which is effective in inhibiting the BET bromodomain receptor and can be used as a therapeutic medicine for cancer, cell proliferation disorders, inflammatory diseases and autoimmune diseases, sepsis, viral infections.

The above-mentioned problems are solved by the present invention according to the following technical solutions:

A 2-oxo-1,2-dihydrobenzo[cd]indole compound or pharmaceutically acceptable salts, isomers, racemates, prodrugs, cocrystalline complexes, hydrates, or solvates thereof, having a structure represented by formula I, II, III or IV:

In formula I, R₁ is selected from H or C₁-C₄ linear or branched alkyl; R₂ is selected from C₁-C₇ alkyl, C₁-C₄ alkylene-R₆ or C₀-C₄ alkylene-R₇-cyclic ring; wherein R₆ is selected from —OR₈, —COR₈, —CONHR₈, —COOR₈, —S(O)_mR₈, —S(O)_mR₈, —NHCOOR₈, —NHCOR₈ or —NH₂, wherein m is 0 or 2, and R₈ is selected from hydrogen or C₁-C₃ alkyl; wherein R₇ is selected from —COR₉, —COOR₉, —OR₉ or unselected, wherein R₉ is selected from C₁-C₃ alkylene; wherein cyclic ring is selected from C₃-C₁₀ cycloalkyl, phenyl, or heterocyclic group;

In formula II, R₁ is selected from H or C₁-C₄ linear or branched alkyl; R₃ is selected from C₁-C₇ alkyl, C₁-C₄ alkylene-R₆ or C₀-C₄ alkylene-R₇-cyclic ring; wherein R₆ is selected from —OR₈, —COR₈, —CONHR₈, —COOR₈, —S(O)_mR₈ or —S(O)_mR₈, wherein m is 0 or 2, and R₈ is selected from hydrogen, C₁-C₃ alkyl; wherein R₇ is selected from —COR₉, —COOR₉, —OR₉ or unselected, wherein R₉ is selected from C₁-C₃ alkylene; wherein cyclic ring is selected from C₃-C₁₀ cycloalkyl, phenyl, or heterocyclic group; In formula III, R₁ is selected from H or C₁-C₄ linear or branched alkyl; R₄ is selected from C₁-C₇ alkyl, C₁-C₄ alkylene-R₆ or C₀-C₄ alkylene-R₇-cyclic ring; wherein R₆ is selected from —OR₈, —COR₈, —CONHR₈, —COOR₈, —S(O)_mR₈, —S(O)_mR₈, —NHCOOR₈ or —NHCOR₈, wherein m is 0 or 2, and R₈ is selected from hydrogen or C₁-C₃ alkyl; wherein R₇ is selected from —COR₉, —COOR₉, —OR₉ or unselected, wherein R₉ is selected from C₁-C₃ alkylene; wherein cyclic ring is selected from C₃-C₁₀ cycloalkyl, phenyl, or heterocyclic group;

In formula IV, R₁ is selected from H or C₁-C₄ linear or branched alkyl; R₅ is selected from C₁-C₇ alkyl, C₁-C₄ alkylene-R₆ or C₀-C₄ alkylene-R₇-cyclic ring; wherein R₆ is selected from —OR₈, —COR₈, —CONHR₈, —COOR₈, —S(O)_mR₈, —S(O)_mR₈, —NHCOOR₈ or —NHCOR₈, wherein in is 0 or 2, and R₈ is selected from hydrogen, C₁-C₃ alkyl; wherein R₇ is selected from —COR₉, —COOR₉, —OR₉ or unselected, wherein R₉ is selected from C₁-C₃ alkylene; wherein cyclic ring is selected from C₃-C₁₀ cycloalkyl, phenyl, or heterocyclic group;

Preferably, the R₁ in formula I, II, III and IV is selected from H, methyl, ethyl, propyl, isopropyl or tert-butyl.

Preferably, in formula I, the cyclic ring in the C₀-C₄ alkylene-R₇-cyclic ring is selected from cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, phenyl, naphthyl, azetidine, oxetane, azacyclopentane, oxacyclopentane, azacyclohexane, oxacyclohexane, azacyclohexyl, imidazol-2-one ring, imidazolyl, furyl, thienyl, oxazolyl, isoxazolyl, pyrimidinyl, pyrrolyl, piperazinyl, tetrahydropyrrolyl, piperidinyl, morpholinyl, 1,3-dioxolanyl or benzo[d]thiazolyl, and these cycloalkyls are substituted by 0, 1, 2 or 3 group(s) selected from halogen, methyl, ethyl, propyl, isopropyl, tert-butyl, trifluoromethyl, cyano, nitro, amino, amide, —COOR₁₀, —COR₁₀, —OR₁₀, —NHCOR₁₀, —NHCOOR₁₀, —C₆H₅R₁₁, morpholinyl, piperidinyl, tetrahydrofuranyl or pyridyl, wherein R₁₀ is selected from hydrogen, C₁-C₄ alkyl or phenyl, and R₁₁ is selected from C₁-C₄ alkyl, halogen, acetyl, methoxy or ethoxy;

In formula II, the cyclic ring in the C₀-C₄ alkylene-R₇-cyclic ring is selected from cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, phenyl, azetidine, oxetane, azacyclopentane, oxacyclopentane, azacyclohexane, oxacyclohexane, azacyclohexyl, furyl, thienyl, oxazolyl, isoxazolyl, pyrimidinyl, pyrrolyl, tetrahydropyrrolyl, piperidinyl, morpholinyl, 1,3-dioxolanyl or benzo[d]thiazolyl, and these cycloalkyls are substituted by 0, 1, 2 or 3 group(s) selected from halogen, methyl, ethyl, propyl, isopropyl, tert-butyl, trifluoromethyl, cyano, carboxyl, nitro, amino, —CONH₂, —COOR₁₀, —COR₁₀, —OR₁₀, —NHCOR₁₀, —NHCOOR₁₀, —C₆H₅R₁₁, morpholinyl, piperidinyl, tetrahydrofuranyl or pyridyl, wherein R₁₀ is selected from hydrogen, C₁-C₄ alkyl or phenyl, and R_u is selected from C₁-C₄ alkyl, halogen, acetyl, methoxy or ethoxy;

In formula III, the cyclic ring in the C₀-C₄ alkylene-R₇-cyclic ring is selected from cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, phenyl, azetidine, oxetane, azacyclopentane, oxacyclopentane, azacyclohexane, oxacyclohexane, azacyclohexyl, imidazol-2-one ring, imidazolyl, furyl, thienyl, oxazolyl, isoxazolyl, pyrimidinyl, pyrrolyl, piperazinyl, tetrahydropyrrolyl, piperidinyl, morpholinyl, 1,3-dioxolanyl or benzo[d]thiazolyl, and these cycloalkyls are substituted by 0, 1, 2 or 3 group(s) selected from halogen, methyl, ethyl, propyl, isopropyl, tert-butyl, trifluoromethyl, cyano, nitro, amino, —CONH₂, —COOR₁₀, —COR₁₀, —OR₁₀, —NHCOR₁₀, —NHCOOR₁₀, —C₆H₅R₁₁, morpholinyl, piperidinyl, tetrahydrofuranyl or pyridyl, wherein R₁₀ is selected from hydrogen, C₁-C₄ alkyl and phenyl, and R₁₁ is selected from C₁-C₄ alkyl, halogen, acetyl, methoxy or ethoxy;

In formula IV, the cyclic ring in the C₀-C₄ alkylene-R₇-cyclic ring is selected from cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, phenyl, azetidine, oxetane, azacyclopentane, oxacyclopentane, azacyclohexane, oxacyclohexane, azacyclohexyl, imidazol-2-one ring, furyl, thienyl, oxazolyl, isoxazolyl, pyrrolyl, piperazinyl, tetrahydropyrrolyl, piperidinyl, morpholinyl, 1,3-dioxolanyl or 1H-indolyl, and these heterocyclic rings can be substituted by 0, 1, 2 or 3 group(s) selected from halogen, methyl, ethyl, propyl, isopropyl, tert-butyl, trifluoromethyl, nitro, amino, amide, —COOR₉, —COR₉, —OR₉, —NHCOR₉, —NHCOOR₉, —C₆H₅R₁₀, morpholinyl, piperidinyl, tetrahydrofuranyl and pyridyl, wherein R₉ is selected from C₁-C₄ alkyl and phenyl, and R₁₀ is selected from hydrogen, C₁-C₄ alkyl, halogen, acetyl, methoxy or ethoxy.

More preferably, in formula I, wherein C₁-C₇ alkyl is selected from methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, n-pentyl, n-hexyl or n-heptyl; for C₁-C₄ alkylene-R₆, R₆ is selected from —OR₈, —COR₈, —CONHR₈, —COOR₈, —S(O)_mR₈, —S(O)_mR₈, —NHCOOR₈ and —NHCOR₈, wherein m is 0 or 2, and R₈ is selected from hydrogen, methyl, ethyl, propyl, tert-butyl; for C₀-C₄ alkylene-R₇-cyclic ring, R₇ is selected from —COR₉, —COOR₉, —OR₉ or unselected, wherein R₉ is selected from C₁-C₃ alkylene, and the cyclic ring is selected from cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, phenyl, azetidine, oxetane, azacyclopentane, oxacyclopentane, azacyclohexane, oxacyclohexane, azacyclohexyl, imidazol-2-one ring or 1,3-dioxolanyl, and these cycloalkyls are substituted by 0, 1, 2 or 3 group(s) selected from halogen, methyl, ethyl, propyl, isopropyl, tert-butyl, trifluoromethyl, cyano, nitro, amino, amide, —COOR₁₀, —COR₁₀, —OR₁₀, —NHCOR₁₀, —NHCOOR₁₀, —C₆H₅R_II, morpholinyl, piperidinyl, tetrahydrofuranyl or pyridyl, wherein R₁₀ is selected from hydrogen, C₁-C₄ alkyl and phenyl, and R₁₁ is selected from methyl, ethyl, propyl, fluorine, chlorine, bromine, acetyl, methoxy, ethoxy.

More preferably, in formula II, wherein C₁-C₇ alkyl is selected from methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, n-pentyl, n-hexyl or n-heptyl; for C₁-C₄ alkylene-R₆, R₆ is selected from —OR₈, —COR₈, —CONHR₈, —COOR₈, —S(O)_mR₈, —S(O)_mR₈, —NHCOOR₈ or —NHCOR₈, wherein m is 0 or 2, and R₈ is selected from hydrogen, methyl, ethyl, propyl, tert-butyl; for C₀-C₄ alkylene-R₇-cyclic ring, R₇ is selected from —COR₉, —COOR₉, —OR₉ or unselected, wherein R₉ is selected from C₁-C₃ alkylene, and the cyclic ring is selected from cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, phenyl, azetidine, oxetane, azacyclopentane, oxacyclopentane, azacyclohexane, oxacyclohexane, azacyclohexyl, furyl, thienyl, oxazolyl, isoxazolyl, pyrimidinyl, pyrrolyl, tetrahydropyrrolyl, piperidinyl, morpholinyl, 1,3-dioxolanyl or benzo[d]thiazolyl, and these cycloalkyls are substituted by 0, 1, 2 or 3 group(s) selected from halogen, methyl, ethyl, propyl, isopropyl, tert-butyl, trifluoromethyl, cyano, nitro, amino, amide, —COOR₁₀, —COR₁₀, —OR₁₀, —NHCOR₁₀, —NHCOOR₁₀, —C₆H₅R₁₁, morpholinyl, piperidinyl, tetrahydrofuranyl and pyridyl, wherein R₁₀ is selected from hydrogen, C₁-C₄ alkyl and phenyl, and R₁₁ is selected from methyl, ethyl, propyl, fluorine, chlorine, bromine, acetyl, methoxy or ethoxy.

More preferably, in formula III, wherein C₁-C₇ alkyl is selected from methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl; for C₁-C₄ alkylene-R₆, R₆ is selected from —OR₈, —COR₈, —CONHR₈, —COOR₈, —S(O)_mR₈, —NHCOOR₈ or —NHCOR₈, wherein m is 0 or 2, and R₈ is selected from hydrogen, methyl, ethyl, propyl or tert-butyl; for C₀-C₄ alkylene-R₇-cyclic ring, R₇ is selected from —COR₉, —COOR₉, —OR₉ or unselected, wherein R₉ is selected from C₁-C₃ alkylene, and the cyclic ring is selected from cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, phenyl, azetidine, oxetane, azacyclopentane, oxacyclopentane, azacyclohexane, oxacyclohexane, azacyclohexyl, imidazol-2-one ring, imidazolyl, furyl, thienyl, oxazolyl, isoxazolyl, pyrimidinyl, pyrrolyl, piperazinyl, tetrahydropyrrolyl, piperidinyl, morpholinyl, 1,3-dioxolanyl or benzo[d]thiazolyl, and these cycloalkyls are substituted by 0, 1, 2 or 3 group(s) selected from halogen, methyl, ethyl, propyl, isopropyl, tert-butyl, trifluoromethyl, cyano, nitro, amino, amide, —COOR₁₀, —COR₁₀, —OR₁₀, —NHCOR₁₀, —NHCOOR₁₀, —C₆H₅R₁₁, morpholinyl, piperidinyl, tetrahydrofuranyl and pyridyl, wherein R₁₀ is selected from hydrogen, C₁-C₄ alkyl and phenyl, and R₁₁ is selected from methyl, ethyl, propyl, fluorine, chlorine, bromine, acetyl, methoxy or ethoxy.

More preferably, in formula IV, wherein C₁-C₇ alkyl is selected from methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, n-pentyl, n-hexyl or n-heptyl; for C₁-C₄ alkylene-R₆, R₆ is selected from —OR₈, —COR₈, —CONHR₈, —COOR₈, —S(O)_mR₈ or —NHCOOR₈, —NHCOR₈, wherein m is 0 or 2, and R₈ is selected from hydrogen, methyl, ethyl, propyl, tert-butyl; for C₀-C₄ alkylene-R₇-cyclic ring, R₇ is selected from —COR₉, —COOR₉, —OR₉ or unselected, wherein R₉ is selected from C₁-C₃ alkylene, and the cyclic ring is selected from cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, phenyl, azetidine, oxetane, azacyclopentane, oxacyclopentane, azacyclohexane, oxacyclohexane, azacyclohexyl, imidazol-2-one ring, furyl, thienyl, oxazolyl, isoxazolyl, pyrrolyl, piperazinyl, tetrahydropyrrolyl, piperidinyl, morpholinyl, 1,3-dioxolanyl or 1H-indolyl, and these cycloalkyls are substituted by 0, 1, 2 or 3 group(s) selected from halogen, methyl, ethyl, propyl, isopropyl, tert-butyl, trifluoromethyl, cyano, nitro, amino, amide, —COOR₁₀, —COR₁₀, —OR₁₀, —NHCOR₁₀, —NHCOOR₁₀, —C₆H₅R₁₁, morpholinyl, piperidinyl, tetrahydrofuranyl or pyridyl, wherein R₁₀ is selected from hydrogen, C₁-C₄ alkyl and phenyl, and R₁₁ is selected from methyl, ethyl, propyl, fluorine, chlorine, bromine, acetyl, methoxy or ethoxy.

In particular embodiments, the compound of formula I, II, III, IV is selected from the group consisting of:

• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)butane-1-sulfonamide;
• 2-chloro-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-4-fluorobenzenesulfonamide;
• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)thiophene-2-sulfonamide;
• 5-chloro-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-2-methoxybenzenesulfonamide;
• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)cyclohexanesulfonamide;
• 2-(N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)sulfamoyl)benzoate;
• 2-(N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)sulfamoyl)benzoic acid;
• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)benzenesulfonamide;
• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-4-fluorobenzenesulfonamide;
• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-3-fluorobenzenesulfonamide;
• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)ethanesulfonamide;
• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-4-methoxybenzenesulfonamide;
• 4-cyano-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)benzenesulfonamide;
• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-4-nitrobenzenesulfonamide;
• 4-(tert-butyl)-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)benzenesulfonamide;
• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-4-(trifluoromethoxy)benzenesulfonamide;
• 3-chloro-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-2-fluorobenzenesulfonamide;
• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-4-methylbenzenesulfonamide;
• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-2,4-difluorobenzenesulfonamide;
• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)propane-1-sulfonamide;
• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)cyclopentanesulfonamide;
• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-4-(trifluoromethyl)benzenesulfonamide;
• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-3-(methylsulfonyl)benzenesulfonamide;
• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)naphthalene-2-sulfonamide;
• 4-(N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)sulfamoyl)benzoate;
• 4-(N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)sulfamoyl)benzoic acid;
• 3-(N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)sulfamoyl)benzoate;
• 3-(N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)sulfamoyl)benzoic acid;
• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-2,3-dihydrobenzo[b][1,4]dioxine-6-sulfonamide;
• 2-bromo-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)benzenesulfonamide;
• 5-bromo-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-2-methoxybenzenesulfonamide;
• 2,6-dichloro-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)benzenesulfonamide;
• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-2,3-dimethoxybenzenesulfonamide;
• 3,5-dichloro-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)benzenesulfonamide;
• 2,3-dichloro-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)benzenesulfonamide;
• 4-((N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)sulfamoyl)methyl)benzoate;
• 4-((N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)sulfamoyl)methyl)benzoic acid;
• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-1-(3-fluorophenyl)methanesulfonamide;
• 3-((N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)sulfamoyl)methyl)benzoate;
• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-1-(4-(trifluoromethyl)phenyl)methanesulfonamide;
• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-1-(p-tolyl)methanesulfonamide;
• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-1-(2-fluorophenyl)methanesulfonamide;
• 1-(4-chlorophenyl)-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)methanesulfonamide;
• 1-(4-cyanophenyl)-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)methanesulfonamide;
• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-1-(4-fluorophenyl)methanesulfonamide;
• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-4-fluorobenzamide;
• 2-(4-chlorophenyl)-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)acetamide;
• 2-(3,4-dimethoxyphenyl)-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)acetamide;
• 2-(2,4-dichlorophenyl)-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)acetamide;
• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-3-phenylpropanamide;
• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-4,4,4-trifluorobutanamide;
• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)propionamide;
• 4-chloro-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)benzamide;
• N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-2-(p-tolyl)acetamide;
• (E)-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-3-(furan-2-yl)acrylamide;
• 1-ethyl-6-((3-phenylpropyl)amino)benzo[cd]indol-2(1H)-one;
• 1-ethyl-6-((3-morpholinopropyl)amino)benzo[cd]indol-2(1H)-one;
• 1-ethyl-6-((4-methoxybenzyl)amino)benzo[cd]indol-2(1H)-one;
• 1-ethyl-6-((4-methylbenzyl)amino)benzo[cd]indol-2(1H)-one;
• 1-ethyl-6-((4-(trifluoromethyl)benzyl)amino)benzo[cd]indol-2 (1H)-one;
• 6-((4-chlorobenzyl)amino)-1-ethylbenzo[cd]indol-2(1H)-one;
• 1-ethyl-6-((4-fluorobenzyl)amino)benzo[cd]indol-2(1H)-one;
• N-((1-acetylpiperidin-4-yl)methyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• 1-((1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole)-6-sulfonamido)cyclohexane-1-carboxamide;
• 1-ethyl-N-((3-isopropyl-4,5-dihydroisoxazol-5-yl)methyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• N-((3,5-dimethyl-4,5-dihydroisoxazol-5-yl)methyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• N-(4-acetylphenyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• N-(2-chlorobenzyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• 1-ethyl-N-(2-fluorobenzyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• N-(1-acetylpiperidin-4-yl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• Tert-butyl4-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)piperidine-1-carboxylate;
• N-cyclopentyl-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• Ethyl1-((1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)methyl)cyclopentanecarboxylate;
• 1-((1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)methyl)cyclopentanecarboxylic acid;
• N-(4-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)phenyl)acetamide;
• 2-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)benzoic acid;
• 1-ethyl-N-(4-fluorophenyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• N-butyl-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• N-(2-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)ethyl)acetamide;
• 1-ethyl-N-(2-(methylsulfonyl)ethyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• 1-ethyl-2-oxo-N-(2-(2-oxoimidazolidin-1-yl)ethyl)-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• Tert-butyl(4-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)butyl)carbamate;
• N-(5-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)pyridin-2-yl)acetamide;
• Tert-butyl3-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)pyrrolidine-1-carboxylate;
• Tert-butyl3-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)azetidine-1-carboxylate;
• N-(2-cyclohexylethyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• 1-ethyl-2-oxo-N-(pyrrolidin-3-yl)-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• N-(azetidin-3-yl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• 1-ethyl-N-hexyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• 1-ethyl-2-oxo-N-(2-(pyrrolidin-1-yl)ethyl)-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• 1-ethyl-2-oxo-N-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• 1-ethyl-2-oxo-N-(tetrahydrofuran-3-yl)-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• N-(2-(4-chlorophenoxy)ethyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• N,1-diethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• 1-ethyl-2-oxo-n-pentyl-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• 1-ethyl-N-methyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• N-cyclohexyl-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• Tert-butyl3-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)piperidine-1-carboxylate;
• 1-ethyl-N-isobutyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• 1-ethyl-2-oxo-N-propyl-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• 1-ethyl-N-(3-(4-methylpiperazin-1-yl)propyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• 1-ethyl-2-oxo-N-(2-(piperidin-1-yl)ethyl)-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• N-(4,4-diethoxybutyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• Ethyl 3-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)propanoate;
• 1-ethyl-N-((1-ethylpyrrolidin-2-yl)methyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• 1-ethyl-N-(1-methylpiperidin-4-yl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• N-cycloheptyl-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• 1-ethyl-2-oxo-N-(tetrahydro-2H-pyran-4-yl)-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• Tert-butyl4-(2-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)ethyl)piperazine-1-carboxylate;
• N-cyclohexyl-1-methyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• N-butyl-1-methyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• N-cyclohexyl-2-oxo-1-propyl-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• 2-oxo-N, 1-dipropyl-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• N-butyl-2-oxo-1-propyl-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• N-butyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• N-butyl-1-isobutyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• N-cyclohexyl-1-isobutyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• N-cyclohexyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• N-(3-acetylphenyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• N-(4-chlorophenyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• 1-ethyl-2-oxo-N-phenyl-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• N-(2-chlorophenyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;
• N-(3-chlorophenyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide;

In some embodiments, the present invention provides a method of treating a conditions or disease by administering a therapeutically effective amount of compounds of structural formula I, II, III, IV or pharmaceutically acceptable salts, isomers, racemates, prodrugs, cocrystalline complexes, hydrates, and solvates thereof. The disease or condition of interest is treatable by inhibition of BET bromodomains, for Example, a cancer, a cellar proliferative disorder, an inflammatory condition, an autoimmune disorder, sepsis, or a viral infection.

Preferably, the disease to be treated by a compound and method of the present invention is cancer. Examples of treatable cancers include, but are not limited to, adrenal cancer, acinic cell carcinoma, acoustic neuroma, acral lentiginous melanoma, acrospiroma, acute eosinophilic leukemia, acute erythroid leukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, acute monocytic leukemia, actue promyelocytic leukemia, adenocarcinoma, adenoid cystic carcinoma, adenoma, adenomatoid odontogenic tumor, adenosquamous carcinoma, adipose tissue neoplasm, adrenocortical carcinoma, adult T-cell leukemia/lymphoma, aggressive NK-cellieukemia, AIDS-related lymphoma, alveolar rhabdomyosarcoma, alveolar soft part sarcoma, ameloblastic fibroma, anaplastic large cell lymphoma, anaplastic thyroid cancer, angioimmunoblastic T-cell lymphoma, angiomyolipoma, angiosarcoma, astrocytoma, atypical teratoid rhabdoid tumor, B-cell chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, B-cell lymphoma, basal cell carcinoma, biliary tract cancer, bladder cancer, blastoma, bone cancer, Brenner tumor, Brown tumor, Burkitt's lymphoma, breast cancer, brain cancer, carcinoma, carcinoma in situ, carcmosarcoma, cartilage tumor, cementoma, myeloid sarcoma, chondroma, chordoma, choriocarcinoma, choroid plexus papilloma, clear-cell sarcoma of the kidney, craniopharyngioma, cutaneous T-cell lymphoma, cervical cancer, colorectal cancer, Degos disease, desmoplastic small round cell tumor, diffuse large B-cell lymphoma, dysembryoplastic neuroepithelial tumor, dysgerminoma, embryonal carcinoma, endocrine gland neoplasm, endodermal sinus tumor, enteropathy-associated T-cell lymphoma, esophageal cancer, fetus in fetu, fibroma, fibrosarcoma, follicular lymphoma, follicular thyroid cancer, ganglioneuroma, gastrointestinal cancer, germ cell tumor, gestational choriocarcinoma, giant cell fibroblastoma, giant cell tumor of the bone, glial tumor, glioblastoma multiforme, glioma, gliomatosis cerebri, glucagonoma, gonadoblastoma, granulosa cell tumor, gynandroblastoma, gallbladder cancer, gastric cancer, hairy cell leukemia, hemangioblastoma, head and neck cancer, hemangiopericytoma, hematological malignancy, hepatoblastoma, hepatosplenic T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, invasive lobular carcinoma, intestinal cancer, kidney cancer, laryngeal cancer, lentigo maligna, lethal midline carcinoma, leukemia, leydig cell tumor, liposarcoma, lung cancer, lymphangioma, lymphangiosarcoma, lymphoepithelioma, lymphoma, acute lymphocytic leukemia, acute myelogeous leukemia, chronic lymphocytic leukemia, liver cancer, small cell lung cancer, non-small cell lung cancer, MALT lymphoma, malignant fibrous histiocytoma, malignant peripheral nerve sheath tumor, malignant triton tumor, mantle cell lymphoma, marginal zone B-cell lymphoma, mast cell leukemia, mediastinal germ cell tumor, medullary carcinoma of the breast, medullary thyroid cancer, medulloblastoma, melanoma, meningioma, merkel cell cancer, mesothelioma, metastatic urothelial carcinoma, mixed Mullerian tumor, mucinous tumor, multiple myeloma, muscle tissue neoplasm, mycosis fungoides, myxoid liposarcoma, myxoma, myxosarcoma, nasopharyngeal carcinoma, neunnoma, neuroblastoma, neurofibroma, neuroma, nodular melanoma, ocular cancer, oligoastrocytoma, oligodendroglioma, oncocytoma, optic nerve sheath meningioma, optic nerve tumor, oral cancer, osteosarcoma, ovarian cancer, Pancoast tumor, papillary thyroid cancer, paraganglioma, pinealoblastoma, pineocytoma, pituicytoma, pituitary adenoma, pituitary tumor, plasmacytoma, polyembryoma, precursor Tlymphoblastic lymphoma, primary central nervous system lymphoma, primary effusion lymphoma, preimary peritoneal cancer, prostate cancer, pancreatic cancer, pharyngeal cancer, pseudomyxoma periotonei, renal cell carcinoma, renal medullary carcinoma, retinoblastoma, rhabdomyoma, rhabdomyosarcoma, Richter's transformation, rectal cancer, sarcoma, Schwannomatosis, seminoma, Sertoli cell tumor, sex cord-gonadal stromal tumor, signet ring cell carcinoma, skin cancer, small blue round cell tumors, small cell carcinoma, soft tissue sarcoma, somatostatinoma, soot wart, spinal tumor, splenic marginal zone lymphoma, squamous cell carcinoma, synovial sarcoma, Sezary's disease, small intestine cancer, squamous carcinoma, stomach cancer, T-cell lymphoma, testicular cancer, thecoma, thyroid cancer, transitional cell carcinoma, throat cancer, urachal cancer, urogenital cancer, urothelial carcinoma, uveal melanoma, uterine cancer, verrucous carcinoma, visual pathway glioma, vulvar cancer, vaginal cancer.

Preferably, the present invention provides a method of treating a benign proliferative disorder, such as, but are not limited to, benign soft tissue tumors, bone tumors, brain and spinal tumors, eyelid and orbital tumors, granuloma, lipoma, meningioma, multiple endocrine neoplasia, nasal polyps, pituitary tumors, prolactinoma, pseudotumor cerebri, seborrheic keratoses, stomach polyps, thyroid nodules, cystic neoplasms of the pancreas, hemangiomas, vocal cord nodules, polyps, and cysts, Castleman disease, chronic pilonidal disease, dermatofibroma, pilar cyst, pyogenic granuloma, and juvenile polyposis syndrome.

Preferably, the compounds and methods of the present invention also treat infectious and noninfectious inflammatory events and autoimmune and other inflammatory diseases by administration of an effective amount of a present compound to a mammal, in particular a human in need of such treatment. Examples of autoimmune and inflammatory diseases, disorders, and syndromes treated using the compounds and methods described herein include inflammatory pelvic disease, urethritis, skin sunburn, sinusitis, pneumonitis, encephalitis, meningitis, myocarditis, nephritis, osteomyelitis, myositis, hepatitis, gastritis, enteritis, dermatitis, gingivitis, appendictitis, pancreatitis, cholocystitus, agammaglobulinemia, psoriasis, allergy, Crohn's disease, irrtiable bowel syndrome, ulcerative colitis, Sjogren's disease, tissue graft rejection, hyperacute rejection of transplanted organs, asthma, allergic rhinitis, chronic obstructive pulmonary disease (COPD), autoimmune polyglandular disease (also known as autoimmune polyglandular syndrome), autoimmune alopecia, pernicious anemia, glomerulonephritis, dermatomyositis, multiple sclerosis, scleroderma, vasculitis, autoimmune hemolytic and thrombocytopenic states, Goodpasture's syndrome, athersclerosis, Addison's disease, Parkinson's disease, Alzheimer's disease, Type I diabetes, septic shock, systemic lupus erythematosus (SLE), rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, osteoarthritis, chronic idiopathic thrombocytopenic purpura, Waldenstrom macroglobulinemia, myasthenia gravis, Hashimoto's thyroiditis, atopic dermatitis, degenerative joint disease, vitiligo, autoimmune hypopituatarism, Guillain-Barre syndrome, Behcet's disease, scleracierma, mycosis fungoides, acute inflammatory responses (such as acute respiratory distress syndrome and ischemia/reperfusion injury), and Graves' disease.

Preferably, the invention further provides a method for treating viral infections and diseases. Examples of viral infections and diseases treated using the compounds and methods described herein include episome-based DNA viruses including, but not limited to, human papillomavirus, Herpesvirus, Epstein-Barr virus, human immunodeficiency virus, hepatis B virus, and hepatitis C virus.

A compound of structural formula I, II, II, IV can be administered by any suitable route, for Example by oral, buccal, inhalation, sublingual, rectal, vaginal, intracisternal or intrathecal through lumbar puncture, transurethral, nasal, percutaneous, trans dermal, or parenteral (including intravenous, intramuscular, subcutaneous, intracoronary, intradermal, intramammary, intraperitoneal, intraarticular, intrathecal, retrobulbar, intrapulmonary injection and/or surgical implantation at a particular site) administration.

In some embodiments, the present invention provides a combination of drugs of structural formula I, II, III, IV or pharmaceutically acceptable salts, isomers, racemates, prodrugs, cocrystalline complexes, hydrates, and solvates thereof.

In some embodiments, the composite can be showed as liquid, semi-liquid or solid form. The method is suitable for the way the medicine is used. The composite can be administered by any suitable route, for Example by oral, parenteral, intraperitoneal, intravenous, subcutaneous, sublingual, intramuscular, rectal, buccal, intranasal, liposome.

In some embodiments, the oral composite can be showed as solid, gel or liquid form. Solid formulations include, but are not limited to, tablets, capsules, granules and bulk powder. These formulations can contain adhesive, thinner, disintegrant, lubricant, flux, sweetener and deodorant. Adhesive include, but are not limited to, microcrystalline cellulose, glucose solution, Arabic jelly, gelatin solution, sucrose and starch paste; Lubricant include, but are not limited to, talc, starch, magnesium stearate, calcium stearate, stearic acid; Thinner include, but are not limited to, lactose, sucrose, starch, glycose and dicalcium phosphate; Flux include, but are not limited to, silicon dioxide; Disintegrant include, but are not limited to, crosslinked carboxymethyl cellulose sodium, starch hydroxyacetate, alginate, corn starch, potato starch, methyl cellulose, AGAR and carboxymethyl cellulose.

In some embodiments, the composite can be formulated for parenteral administration by injection, e.g., intravenous, intramuscular or intravenous injection. Injection can be made as pharmaceutically acceptable forms, e.g., liquid, solution or suspension, a solid form suitable for dissolving or suspending in a liquid prior to injection or an emulsion. The composite can be readily combined with pharmaceutically acceptable carriers well-known in the art, e.g., waterborne carriers, non-aqueous carriers, antimicrobial agents, isotonic agents, buffers, antioxidants, suspensions and dispersants, emulsifiers, chelating agents and other pharmaceutically acceptable substances. Waterborne carriers include, but are not limited to, sodium chloride injection, forest gel injection, isotonic glucose injection, sterile water injection, glucose and lactated Ringer's injection; Non-aqueous carriers include, but are not limited to, fixed oil, cottonseed oil, corn oil, sesame oil and peanut oil; Antimicrobial agents include, but are not limited to, M-cresol, benzyl alcohol, chlorobutanol, benzalkonium chloride; Isotonic agents include, but are not limited to, sodium chloride and glucose; Buffers include, but are not limited to, phosphate and citrate.

In some embodiments, the composite can be formulated for sterile lyophilized powder injection. The composite can be dissolved in sodium phosphate buffer solution (include glucose or other suitable excipient), and then the solution was sterile filtered, followed by lyophilization to give the desired formulation.

As an additional embodiment: the present invention provides compounds of a novel 2-oxo-1,2-dihydrobenzo[cd]indole as scaffold; These compounds can inhibite BET bromodomain protein. Diseases and conditions treatable by a method of the present invention include, but are not limited to, cancers and other proliferative disorders, inflammatory diseases, sepsis, autoimmune disease, and viral infectios.

In the compounds of the present invention, when any variable (e.g., R₁, R₂, etc.) appears more than once in any component, the definition of each occurrence is independent of the other occurrence of each occurrence. Likewise, a combination of substituents and variables is allowed, as long as the combination stabilizes the compound. The lines from the substituents into the ring system indicate that the indicated bond can be attached to any of the substitutable ring atoms. If the ring system is a polycyclic, it means that the bond is only attached to any suitable carbon atom adjacent to the ring. It is to be understood that one of ordinary skill in the art can select the substituents and substitutions of the compounds of the present invention to provide compounds that are chemically stable and readily synthesizable from readily available starting materials by techniques of the art and the methods set forth below. If the substituents themselves are substituted by more than one group, it is to be understood that these groups may be on the same carbon atom or on different carbon atoms as long as the structure is stable. The term “alkyl”, “alkylene” as used herein mean to include branched and straight chain saturated aliphatic hydrocarbon groups having a specific number of carbon atoms. For Example, the definition of “C1-C4” in the “C1-C4” alkyl group includes a group having 1, 2, 3, 4 carbon atoms in a straight chain or branched chain. For Example, the “C1-C4” alkyl group specifically includes methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl and isobutyl. Unless additional defined, alkyl, cycloalkyl and heterocyclyl substituents may be unsubstituted or substituted. For Example, the C1-C4 alkyl group may be substituted by one, two or three substituents selected from halogen, methyl, ethyl, propyl, isopropyl, tert-butyl, trifluoromethyl, cyano, amino, phenyl diazenyl, —CONH₂, —COOR, —COR₇, —OR₇, —NHCOR₇, —NHCOOR₇, —C₆H₅R₈, morpholinyl, piperidinyl, tetrahydrofuranyl, pyridyl, wherein R₇ is selected from C1-C4 alkyl, phenyl; R₈ is optionally substituted with a substituent selected from C1 to C4 alkyl, halogen, acetyl, methoxy, ethoxy.

The present invention includes compounds of formulas I, II, III, IV, and their pharmaceutically acceptable salts and stereoisomers thereof. Pharmaceutically acceptable salts include not only exemplary salts of specific compounds described herein, and also included pharmaceutically acceptable salts from compounds of formula I, II, III, IV or the free form of the compound-specific salt can be isolated using techniques known in the art. For Example, when treated with a suitable dilute aqueous solution of dilute aqueous solution, such as NaOH, K₂CO₃, dilute aqueous ammonia, and NaHCO₃, the free form of formula I, II, III, IV was regenerated. The free form may be different from salt forms in some physical properties, such as the dissociation in polar solvents, but for the purposes of this invention, the acid salts and base salts are comparable to their respective free forms in other pharmaceuticals.

The pharmaceutically acceptable salts of the present invention can be synthesized from compounds containing the basic or acidic moiety by conventional chemical methods. Typically, the salt of the basic compound is prepared by ion exchange chromatography, or free base with reaction of stoichiometric or excess amount of inorganic/organic acid in a suitable solvent or combination of a plurality of solvents. Similarly, salts of acidic compounds are formed by reaction with an appropriate inorganic/organic base.

Thus, the pharmaceutically acceptable salts of the compounds of the present invention include conventional non-toxic salts by the reaction of a compound of the present invention with an inorganic or organic acid. For Example, conventional non-toxic salts include those derived from inorganic acids, e g. from hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, nitric acid; from organic acids, e g. from acetic acid, propionic acid, glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, picric acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, water 2-acetoxy-benzoic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, ethane disulfonic acid, oxalic acid, isethionate, trifluoroacetic acid.

For Example, conventional non-toxic salts include those derived from inorganic bases, e g. from aluminum salts, ammonium salts, calcium salts, copper salts, iron salts, ferrous salts, lithium salts, magnesium salts, manganese salts, manganese salts, potassium salts, sodium salts and zinc salts. Particularly preferred are ammonium salts, calcium salts, magnesium salts, potassium salts and sodium salts; from organic bases, e g., from primary amine, secondary amine, tertiary amine and naturally substituted amines, cyclic amines and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N, N′-dibenzylethylenediamine, diethylamine, 2-diethylamino ethanol, 2-dimethylaminoethanol, aminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucosamine, glucosamine, histidine, hydroxypropylamine, isopropylamine, lysine, methylglucosamine, morpholine, piperazine, piperidine, guanza, polyamine resin, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine.

In addition to the standard methods known in the literature or exemplified in the experimental procedure, the compounds of the present invention can be prepared using the reactions shown in the following schemes. Accordingly, the following illustrative protocols are for illustrative purposes and are not intended to be limited to the listed compounds or any particular substituents. The number of substituents shown in the scheme is not necessarily to be used in the claims. For the sake of clarity, monosubstituted group is attached to a compound showed in invention which is allowed to have a plurality of substituents under the definitions of the formulas I, II, III, IV.

Synthesis of compounds of formula I. The compounds may be prepared by reacting the 1,8-naphthalenedicarboxylic anhydride as a starting material in 6 steps:

Or by reacting the 1,8-naphthalenedicarboxylic anhydride as a starting material in 5 steps:

Synthesis of compounds of formula II. The compounds may be prepared by reacting the 1,8-naphthalenedicarboxylic anhydride as a starting material in 6 steps:

Or by reacting the 1,8-naphthalenedicarboxylic anhydride as a starting material in 5 steps:

Synthesis of compounds of formula III. The compounds may be prepared by reacting the 1,8-naphthalenedicarboxylic anhydride as a starting material in 6 steps:

Or by reacting the 1,8-naphthalenedicarboxylic anhydride as a starting material in 5 steps:

Synthesis of compounds of formula IV. The compounds may be prepared by reacting the 1,8-naphthalenedicarboxylic anhydride as a starting material in 5 steps:

The present invention will be described in greater detail by way of special Examples. The following Examples are offered for illustrative purposes, and are not intended to limit the invention in any manner.

The synthesis of formula I:

1,8-naphthalenedicarboxylic anhydride (11.9 g, 0.06 mol) and hydroxylamine hydrochloride (4.18 g, 0.06 mol) were combined as a solution in pyridine (70 mL). The reaction was conducted under reflux for 1 h followed by cooling to 80° C. To the reaction system mixture was added powdered p-toluenesulfonyl chloride (22.88 g, 0.12 mol). After the addition, the reaction was performed under reflux for 1 h. After cooling to room temperature, the reaction mixture was poured into ice water (200 mL) and stirred to precipitate crystals. The precipitate was filtered and rinsed with additional cool water (100 mL) and saturated NaHCO₃ (100 mL) to give 1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl 4-methyl benzenesulfonate (17 g, 78%) as a yellow solid.

To a solution of 1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl 4-methyl benzenesulfonate (17 g, 0.048 mol) in ethanol (50 mL) and water (40 mL) was added an aqueous solution of sodium hydroxide (2.7 mol/L, 60 mL) at room temperature. The mixture was heated to reflux temperature for 3 h while distilling the ethanol. After the reaction was completed, the reaction mixture was cooled to 75° C., concentrated hydrochloric acid was added dropwise, and a yellow precipitate was formed. Then, the mixture was further cooled. The precipitate was collected by filtration and washed with water (100 mL×2). The resulting crude product was purified by silica gel chromatography with dichloromethane to give Benzo[cd]indol-2(1H)-one (6.65 g, 82%) as a yellow solid. MS (ESI), m/z: M+170.0.

The product benzo[cd]indol-2(1H)-one (6.65 g, 0.04 mol) and NaH (2.81 g, 0.18 mol) were dissolved in DMF (100 mL). Ethyl iodide (7.33 g, 0.047 mol) was added dropwise at 0° C. The reaction mixture was stirred at rt 3 h. The reaction mixture was extracted with ethyl acetate (150 mL×2). The organic layer was washed with brine and dried over Na₂SO₄. The solid was filtered off, and the filtrate was concentrated under reduced pressure. The resulting crude product was purified by silica gel chromatography with petroleum ether/ethyl acetate (10/1, v/v) to yield 1-ethylbenzo[cd]indol-2(1H)-one (6.46 g, 84%) as a yellow oil. MS (ESI), m/z: M⁺ 198.0.

To a solution of 1-ethylbenzo[cd]indol-2(1H)-one (500 mg, 2.53 mmol) in AcOH (5 mL) was added HNO₃ (154 mg, 2.53 mmol) at 0° C. then the reaction mixture was stirred at 50° C. for 1 h. After the reaction was completed, the reaction mixture was cooled to rt. The reaction mixture was extracted with ethyl acetate (150 mL×2). The organic layer was washed with brine and dried over Na₂SO₄. The solid was filtered off, and the filtrate was concentrated under reduced pressure. The resulting crude product was purified by silica gel chromatography with petroleum ether/ethyl acetate (6/1, v/v) to yield 1-ethyl-6-nitrobenzo[cd]indol-2(1H)-one (400 mg, 65%) as a yellow solid.

A reaction mixture of Fe power (462 mg, 8.26 mmol) and NH₄Cl (131 mg, 2.47 m mol) in AcOH (2 mL) and water (20 mL) was heated at 50° C. for 5 min. 1-ethyl-6-nitro benzo[cd]indol-2(1H)-one (400 mg, 1.65 mmol) was dissolved in DMF (10 mL) and added to the reaction mixture. After the reaction was completed, the reaction mixture was cooled to rt. The reaction mixture was extracted with ethyl acetate (150 mL×2). The organic layer was washed with brine and dried over Na₂SO₄. The solid was filtered off, and the filtrate was concentrated under reduced pressure. The resulting crude product was purl fled by silica gel chromatography with petroleum ether/ethyl acetate (3/1, v/v) to yield 6-amino-1-ethylbenzo[cd]indol-2(1H)-one (316 mg, 90%) as a yellow solid.

A reaction mixture of compound 6-amino-1-ethylbenzo[cd]indol-2(1H)-one (80 mg, 0.38 mmol) and butane-1-sulfonyl chloride (89 mg, 0.57 mmol) in pyridine (5 mL) was stir red at 80° C. for 1 h. Dilute HCl was added, the aqueous layer was extracted with ethyl acetate (50 mL×3), and the organic layer was washed with water and brine, dried with Na₂SO₄ and evaporated. The residue was purified by silica gel chromatography with petroleum and ether/ethyl acetate (4/1, v/v) to afford N-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)butane-1-sulfonamide (66 mg, 52%).¹H NMR (400 MHz, CDCl₃) δ 8.21 (d, J=8.4 Hz, 1H), 8.10 (d, J=7.2 Hz, 1H), 7.90-7.69 (m, 1H), 7.53 (d, J=7.6 Hz, 1H), 6.88 (d, J=7.6 Hz, 1H), 6.77 (s, 1H), 3.97 (q, J=7.2 Hz, 2H), 3.27-2.89 (m, 2H), 1.94-1.75 (m, 2H), 1.51-1.30 (m, 5H), 0.90 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, CDCl₃) δ 8.22 (d, J=8.4 Hz, 1H), 8.06 (d, J=7.2 Hz, 1H), 7.86 (dd, J=8.8, 5.6 Hz, 1H), 7.82-7.65 (m, 1H), 7.33 (dd, J=8.0, 2.4 Hz, 1H), 7.26 (s, 1H), 7.13 (d, J=7.6 Hz, 1H), 7.00-6.83 (m, 1H), 6.71 (d, J=7.6 Hz, 1H), 3.91 (q, J=7.2 Hz, 2H), 1.32 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, CDCl₃) δ 8.03 (d, J=7.2 Hz, 1H), 7.92 (d, J=8.4 Hz, 1H), 7.74-7.58 (m, 1H), 7.52 (d, J=5.2 Hz, 1H), 7.41 (d, J=3.6 Hz, 1H), 7.31 (d, J=7.6 Hz, 1H), 7.01-6.93 (m, 1H), 6.91 (s, 1H), 6.82 (d, J=7.6 Hz, 1H), 3.95 (q, J=7.2 Hz, 2H), 1.36 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, CDCl₃) δ 8.18 (d, J=8.4 Hz, 1H), 8.05 (d, J=7.2 Hz, 1H), 7.71 (dd, J=15.2, 5.2 Hz, 2H), 7.45 (dd, J=8.8, 2.4 Hz, 1H), 7.25 (s, 1H), 7.13 (d, J=7.6 Hz, 1H), 7.00 (d, J=8.8 Hz, 1H), 6.72 (d, J=7.6 Hz, 1H), 4.08 (s, 3H), 3.91 (q, J=7.2 Hz, 2H), 1.32 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, CDCl₃) δ 8.23 (d, J=8.4 Hz, 1H), 8.09 (d, J=7.2 Hz, 1H), 7.78 (t, J=7.6 Hz, 1H), 7.55 (d, J=7.6 Hz, 1H), 7.00-6.72 (m, 2H), 3.96 (q, J=7.2 Hz, 2H), 3.21-2.96 (m, 1H), 2.23 (d, J=112.0 Hz, 2H), 1.87 (d, J=7.6 Hz, 2H), 1.65-1.61 (m, 4H), 1.37 (t, J=7.2 Hz, 3H), 1.19 (d, J=9.2 Hz, 2H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, CDCl₃) δ 8.27 (s, 1H), 8.14 (d, J=8.4 Hz, 1H), 8.01 (d, J=7.2 Hz, 1H), 7.86 (d, J=7.2 Hz, 1H), 7.72-7.49 (m, 3H), 7.41 (t, J=7.6 Hz, 1H), 7.33-7.14 (m, 2H), 6.75 (d, J=7.6 Hz, 1H), 4.12 (s, 3H), 3.92 (q, J=7.2 Hz, 2H), 1.34 (t, J=7.2 Hz, 3H).

The synthesis of methyl 2-(N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)sulfamoyl)benzoate can refer Example 6.

Methyl 2-(N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)sulfamoyl)benzoate (50 mg, 0.12 mmol) was dissolved in THF (5 mL) and 2 mol/L NaOH aqueous solution (5 mL). The mixture was stirred at room temperature for 2 h. The solvent was removed and diluted hydrochloric acid was added dropwise, and a yellow precipitate was formed. The precipitate was collected by filtration and washed with water (10 mL×2). The resulting crude product was purified by recrystallization with petroleum and ether/ethyl acetate to afford 2-(N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)sulfamoyl)benzoic acid (33 mg, 69%) as a yellow solid.¹H NMR (400 MHz, d-DMSO) δ 10.04 (s, 1H), 8.18 (d, J=8.4 Hz, 1H), 7.98 (d, J=7.2 Hz, 1H), 7.75-7.66 (m, 2H), 7.63 (t, J=7.6 Hz, 1H), 7.57 (d, J=8.0 Hz, 1H), 7.45 (t, J=7.6 Hz, 1H), 7.22 (d, J=7.6 Hz, 1H), 7.10 (d, J=7.6 Hz, 1H), 3.87 (q, J=7.2 Hz, 2H), 1.23 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, CDCl₃) δ 8.00 (d, J=7.2 Hz, 1H), 7.90 (d, J=8.4 Hz, 1H), 7.74 (d, J=7.6 Hz, 2H), 7.60 (t, J=7.6 Hz, 1H), 7.54-7.49 (m, 1H), 7.39 (t, J=7.6 Hz, 2H), 7.21 (d, J=7.6 Hz, 1H), 7.06 (s, 1H), 6.77 (d, J=7.6 Hz, 1H), 3.93 (q, J=7.2 Hz, 2H), 1.34 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, d-DMSO) δ 10.29 (s, 1H), 8.03 (dd, J=16.4, 7.6 Hz, 2H), 7.84-7.63 (m, 3H), 7.33 (t, J=8.8 Hz, 2H), 7.13 (s, 2H), 3.87 (q, J=7.2 Hz, 2H), 1.23 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, CDCl₃) δ 8.03 (d, J=7.2 Hz, 1H), 7.91 (d, J=8.4 Hz, 1H), 7.65 (t, J=7.6 Hz, 1H), 7.66-7.45 (m, 2H), 7.38 (dd, J=13.2, 8.0 Hz, 1H), 7.25 (d, J=4.8 Hz, 1H), 7.20 (s, 1H), 6.79 (d, J=7.6 Hz, 1H), 3.94 (q, J=7.2 Hz, 2H), 1.35 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, CDCl₃) δ 8.22 (d, J=8.4 Hz, 1H), 8.10 (d, J=7.2 Hz, 1H), 7.80 (t, J=7.6 Hz, 1H), 7.54 (d, J=7.6 Hz, 1H), 6.93-6.76 (m, 2H), 3.97 (q, J=7.2 Hz, 2H), 3.16 (q, J=7.2 Hz, 2H), 1.43 (t, J=7.2 Hz, 3H), 1.37 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, CDCl₃) δ 8.02 (d, J=7.2 Hz, 1H), 7.95 (d, J=8.4 Hz, 1H), 7.79-7.51 (m, 3H), 7.20 (d, J=7.6 Hz, 1H), 6.89 (s, 1H), 6.84 (d, J=8.8 Hz, 2H), 6.77 (d, J=7.6 Hz, 1H), 3.93 (q, J=7.2 Hz, 2H), 1.35 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, CDCl₃) δ 8.04 (d, J=7.2 Hz, 1H), 7.89 (d, J=8.4 Hz, 1H), 7.85 (d, J=8.4 Hz, 2H), 7.74-7.57 (m, 3H), 7.17 (d, J=7.6 Hz, 1H), 7.11 (s, 1H), 6.79 (d, J=7.6 Hz, 1H), 3.94 (q, J=7.2 Hz, 2H), 1.35 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, CDCl₃) δ 8.25 (d, J=8.8 Hz, 2H), 8.05 (d, J=7.2 Hz, 1H), 7.92 (d, J=9.2 Hz, 3H), 7.67 (t, J=7.6 Hz, 1H), 7.17 (d, J=7.6 Hz, 1H), 6.95 (s, 1H), 6.79 (d, J=7.6 Hz, 1H), 3.94 (q, J=7.2 Hz, 2H), 1.36 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, CDCl₃) δ 7.99 (d, J=7.2 Hz, 1H), 7.78 (d, J=8.4 Hz, 1H), 7.63 (d, J=8.4 Hz, 2H), 7.60-7.48 (m, 1H), 7.37 (d, J=8.4 Hz, 2H), 7.28 (s, 1H), 6.80 (d, J=7.6 Hz, 2H), 3.94 (q, J=7.2 Hz, 2H), 1.36 (t, J=7.2 Hz, 3H), 1.27 (s, 9H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, CDCl₃) δ 8.05 (d, J=7.2 Hz, 1H), 7.86 (d, J=8.4 Hz, 1H), 7.79 (d, J=8.8 Hz, 2H), 7.71-7.53 (m, 1H), 7.23 (d, J=7.6 Hz, 3H), 6.87 (s, 1H), 6.82 (d, J=7.6 Hz, 1H), 3.97 (q, J=7.2 Hz, 2H), 1.38 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, d-DMSO) δ 10.82 (s, 1H), 8.12 (d, J=8.4 Hz, 1H), 8.03 (d, J=6.8 Hz, 1H), 7.82 (dd, J=17.6, 10.0 Hz, 1H), 7.76 (d, J=7.2 Hz, 1H), 7.59 (t, J=7.2 Hz, 1H), 7.28 (t, J=8.0 Hz, 1H), 7.22 (d, J=7.6 Hz, 1H), 7.13 (d, J=7.6 Hz, 1H), 3.87 (q, J=7.2 Hz, 2H), 1.23 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, CDCl₃) δ 8.02 (d, J=7.2 Hz, 1H), 7.93 (d, J=8.4 Hz, 1H), 7.63 (t, J=8.4 Hz, 3H), 7.19 (dd, J=7.6, 5.2 Hz, 3H), 6.85 (s, 1H), 6.77 (d, J=7.6 Hz, 1H), 3.93 (q, J=7.2 Hz, 2H), 2.36 (s, 3H), 1.35 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, CDCl₃) δ 8.14 (d, J=8.4 Hz, 1H), 8.05 (d, J=7.2 Hz, 1H), 7.75-7.70 (m, 2H), 7.23 (d, J=7.6 Hz, 1H), 7.07 (s, 1H), 7.01-6.91 (m, 1H), 6.87 (dd, J=11.6, 5.2 Hz, 1H), 6.75 (d, J=7.6 Hz, 1H), 3.92 (q, J=7.2 Hz, 2H), 1.33 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, CDCl₃) δ 8.22 (d, J=8.0 Hz, 1H), 8.09 (d, J=6.8 Hz, 1H), 7.79 (t, J=7.2 Hz, 1H), 7.53 (d, J=7.2 Hz, 1H), 6.99 (s, 1H), 6.88 (d, J=7.2 Hz, 1H), 3.97 (q, J=7.2 Hz, 2H), 3.30-2.79 (m, 2H), 1.91 (dd, J=14.8, 7.2 Hz, 2H), 1.37 (t, J=6.8 Hz, 3H), 1.02 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, CDCl₃) δ 8.25 (d, J=8.0 Hz, 1H), 8.08 (d, J=6.8 Hz, 1H), 7.77 (t, J=7.2 Hz, 1H), 7.58 (d, J=7.2 Hz, 1H), 7.16 (s, 1H), 6.86 (d, J=7.2 Hz, 1H), 3.96 (q, J=7.2 Hz, 2H), 3.51-3.46 (m, 1H), 2.13-2.03 (m, 4H), 1.95-1.78 (m, 4H), 1.36 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, CDCl₃) δ 8.04 (d, J=6.8 Hz, 1H), 7.96-7.73 (m, 3H), 7.68-7.62 (m, 3H), 7.18 (d, J=7.6 Hz, 1H), 6.88 (s, 1H), 6.79 (d, J=7.2 Hz, 1H), 3.94 (q, J=7.2 Hz, 2H), 1.36 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, d-DMSO) δ 10.49 (s, 1H), 8.14 (d, J=9.6 Hz, 2H), 8.00 (d, J=7.2 Hz, 2H), 7.93 (d, J=7.6 Hz, 1H), 7.77 (t, J=7.6 Hz, 1H), 7.69 (t, J=7.6 Hz, 1H), 7.13 (s, 2H), 3.87 (d, J=7.2 Hz, 2H), 3.17 (s, 3H), 1.23 (t, J=6.8 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, d-DMSO) δ 10.61 (s, 1H), 8.80 (d, J=8.4 Hz, 1H), 8.15 (d, J=8.0 Hz, 1H), 8.04 (d, J=7.6 Hz, 1H), 7.98 (d, J=7.2 Hz, 1H), 7.92 (t, J=7.6 Hz, 2H), 7.72-7.65 (m, 2H), 7.53-7.49 (m, 2H), 7.09 (d, J=7.6 Hz, 1H), 7.02 (d, J=7.6 Hz, 1H), 3.82 (q, J=7.2 Hz, 2H), 1.18 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, d-DMSO) δ 10.46 (s, 1H), 8.04 (d, J=8.4 Hz, 3H), 8.00 (d, J=7.2 Hz, 1H), 7.80 (d, J=8.4 Hz, 2H), 7.70 (t, J=7.6 Hz, 1H), 7.11 (s, 2H), 3.87 (q, J=7.2 Hz, 5H), 1.23 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 7.¹H NMR (400 MHz, d-DMSO) δ 13.41 (s, 1H), 10.44 (s, 1H), 8.17-7.92 (m, 4H), 7.77 (d, J=8.0 Hz, 2H), 7.70 (t, J=7.6 Hz, 1H), 7.11 (s, 2H), 3.86 (q, J=7.2 Hz, 2H), 1.23 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, d-DMSO) δ 10.43 (s, 1H), 8.22 (s, 1H), 8.12 (d, J=7.6 Hz, 1H), 8.04-7.98 (m, 2H), 7.86 (d, J=7.6 Hz, 1H), 7.70-7.61 (m, 2H), 7.11 (s, 2H), 3.93-3.77 (m, 5H), 1.22 (t, J=7.1 Hz, 3H).

The synthesis can refer to Example 7.¹H NMR (400 MHz, d-DMSO) δ 13.27 (s, 1H), 10.39 (s, 1H), 8.21 (s, 1H), 8.10 (d, J=7.6 Hz, 1H), 8.01-7.98 (m, 2H), 7.84 (d, J=7.6 Hz, 1H), 7.68 (t, J=7.6 Hz, 1H), 7.61 (t, J=7.6 Hz, 1H), 7.11 (s, 2H), 3.86 (q, J=7.2 Hz, 2H), 1.22 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, d-DMSO) δ 10.14 (s, 1H), 8.10 (d, J=8.4 Hz, 1H), 8.01 (d, J=6.8 Hz, 1H), 7.73 (t, J=7.6 Hz, 1H), 7.26-7.00 (m, 4H), 6.91 (d, J=8.4 Hz, 1H), 4.25 (d, J=9.2 Hz, 4H), 3.87 (q, J=7.2 Hz, 2H), 1.23 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, CDCl₃) δ 8.26 (d, J=8.4 Hz, 1H), 8.05 (d, J=7.2 Hz, 1H), 7.87 (d, J=7.6 Hz, 1H), 7.80 (d, J=7.6 Hz, 1H), 7.73 (t, J=7.6 Hz, 1H), 7.40 (t, J=7.6 Hz, 1H), 7.36-7.28 (m, 2H), 7.11 (d, J=7.6 Hz, 1H), 6.69 (d, J=7.6 Hz, 1H), 3.90 (q, J=7.2 Hz, 2H), 1.31 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, d-DMSO) δ 10.29 (s, 1H), 8.24 (d, J=8.4 Hz, 1H), 8.02 (d, J=6.8 Hz, 1H), 7.79 (t, J=7.6 Hz, 1H), 7.71 (d, J=8.8 Hz, 1H), 7.61 (s, 1H), 7.24 (d, J=7.6 Hz, 1H), 7.15 (d, J=8.8 Hz, 1H), 7.10 (d, J=7.6 Hz, 1H), 3.98-3.57 (m, 5H), 1.22 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, CDCl₃) δ 8.17 (d, J=8.0 Hz, 1H), 8.05 (d, J=7.2 Hz, 1H), 7.73 (t, J=7.6 Hz, 1H), 7.50 (s, 1H), 7.45 (d, J=8.0 Hz, 2H), 7.38-7.29 (m, 1H), 7.22 (d, J=7.6 Hz, 1H), 6.74 (d, J=7.6 Hz, 1H), 3.92 (q, J=7.2 Hz, 2H), 1.33 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, CDCl₃) δ 8.23 (d, J=8.4 Hz, 1H), 8.04 (d, J=7.2 Hz, 1H), 7.72 (t, J=7.6 Hz, 1H), 7.27 (d, J=4.4 Hz, 1H), 7.22 (s, 1H), 7.11 (d, J=7.6 Hz, 1H), 7.02 (s, 2H), 6.70 (d, J=7.6 Hz, 1H), 4.07 (s, 3H), 3.90 (q, J=7.2 Hz, 2H), 3.67 (s, 3H), 1.31 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, d-DMSO) δ 10.52 (s, 1H), 8.05 (t, J=8.0 Hz, 2H), 7.93 (s, 1H), 7.76 (t, J=7.6 Hz, 1H), 7.60 (s, 2H), 7.29-6.97 (m, 2H), 3.88 (q, J=7.2 Hz, 2H), 1.23 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, d-DMSO) δ 10.77 (s, 1H), 8.24 (d, J=8.0 Hz, 1H), 8.03 (d, J=6.8 Hz, 1H), 7.89 (d, J=8.0 Hz, 1H), 7.80 (dd, J=7.6, 4.0 Hz, 2H), 7.42 (t, J=8.0 Hz, 1H), 7.18 (d, J=7.6 Hz, 1H), 7.09 (d, J=7.6 Hz, 1H), 3.85 (q, J=7.2 Hz, 2H), 1.21 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, CDCl₃) δ 8.10 (d, J=6.8 Hz, 1H), 7.95 (t, J=8.4 Hz, 3H), 7.74 (t, J=7.6 Hz, 1H), 7.52 (d, J=7.6 Hz, 1H), 7.36 (d, J=8.0 Hz, 2H), 6.87 (d, J=7.6 Hz, 1H), 6.82 (s, 1H), 4.43 (s, 2H), 3.97 (q, J=7.2 Hz, 2H), 3.91 (s, 3H), 1.38 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, d-DMSO) δ 12.92 (s, 1H), 9.96 (s, 1H), 8.31 (d, J=8.4 Hz, 1H), 8.08 (d, J=6.8 Hz, 1H), 7.86-7.80 (m, 3H), 7.48 (d, J=7.6 Hz, 1H), 7.43 (d, J=8.0 Hz, 2H), 7.19 (d, J=7.6 Hz, 1H), 4.59 (s, 2H), 3.92 (q, J=6.8 Hz, 2H), 1.27 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, CDCl₃) δ 8.10 (d, J=7.2 Hz, 1H), 7.96 (d, J=8.4 Hz, 1H), 7.74 (t, J=7.6 Hz, 1H), 7.52 (d, J=7.6 Hz, 1H), 7.32-7.13 (m, 2H), 7.04 (t, J=10.4 Hz, 3H), 6.91-6.66 (m, 2H), 4.37 (s, 2H), 3.98 (q, J=7.2 Hz, 2H), 1.38 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, d-DMSO) δ 9.94 (s, 1H), 8.27 (d, J=8.4 Hz, 1H), 8.07 (d, J=6.8 Hz, 1H), 7.88 (d, J=7.8 Hz, 1H), 7.86-7.82 (m, 2H), 7.60 (d, J=7.6 Hz, 1H), 7.51-7.35 (m, 2H), 7.17 (d, J=7.6 Hz, 1H), 4.61 (s, 2H), 3.92 (d, J=7.2 Hz, 2H), 3.79 (s, 3H), 1.27 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, CDCl₃) δ 8.09 (d, J=6.8 Hz, 1H), 7.97 (d, J=8.0 Hz, 1H), 7.73 (t, J=7.6 Hz, 1H), 7.51 (t, J=6.4 Hz, 3H), 7.40 (d, J=7.6 Hz, 2H), 6.94 (s, 1H), 6.86 (d, J=7.6 Hz, 1H), 4.44 (s, 2H), 3.97 (q, J=7.2 Hz, 2H), 1.38 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, d-DMSO) δ 9.84 (s, 1H), 8.32 (d, J=8.4 Hz, 1H), 8.07 (d, J=6.8 Hz, 1H), 7.82 (t, J=7.6 Hz, 1H), 7.47 (d, J=7.6 Hz, 1H), 7.20-7.18 (m, 3H), 7.11 (d, J=7.6 Hz, 2H), 4.42 (s, 2H), 3.92 (q, J=7.2 Hz, 2H), 2.28 (s, 3H), 1.27 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, d-DMSO) δ 10.03 (s, 1H), 8.34 (d, J=8.4 Hz, 1H), 8.08 (d, J=6.8 Hz, 1H), 7.84 (t, J=7.6 Hz, 1H), 7.50 (d, J=7.6 Hz, 1H), 7.41 (t, J=7.2 Hz, 2H), 7.20-7.16 (m, 3H), 4.53 (s, 2H), 3.93 (q, J=7.2 Hz, 2H), 1.27 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, d-DMSO) δ 9.92 (s, 1H), 8.31 (d, J=8.4 Hz, 1H), 8.07 (d, J=6.8 Hz, 1H), 7.83 (t, J=7.6 Hz, 1H), 7.48 (d, J=7.6 Hz, 1H), 7.35 (q, J=8.4 Hz, 4H), 7.18 (d, J=7.6 Hz, 1H), 4.51 (s, 2H), 3.92 (q, J=7.2 Hz, 2H), 1.27 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, CDCl₃) δ 10.01 (s, 1H), 8.29 (d, J=8.0 Hz, 1H), 8.08 (d, J=6.8 Hz, 1H), 7.83 (t, J=7.6 Hz, 1H), 7.78 (d, J=8.0 Hz, 2H), 7.52-7.46 (m, 3H), 7.19 (d, J=7.6 Hz, 1H), 4.64 (s, 2H), 3.92 (q, J=6.8 Hz, 2H), 1.27 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 1.¹H NMR (400 MHz, CDCl₃) δ 8.10 (d, J=7.2 Hz, 1H), 7.96 (d, J=8.4 Hz, 1H), 7.84-7.68 (m, 1H), 7.51 (d, J=7.6 Hz, 1H), 7.25 (d, J=9.2 Hz, 1H), 6.98 (t, J=8.4 Hz, 2H), 6.87 (d, J=7.6 Hz, 1H), 6.71 (s, 1H), 4.36 (s, 2H), 3.98 (q, J=7.2 Hz, 2H), 1.39 (t, J=7.2 Hz, 3H).

The synthesis of formula II:

6-amino-1-ethylbenzo[cd]indol-2(1H)-one can refer to Example 1.

A reaction mixture of 6-amino-1-ethylbenzo[cd]indol-2(1H)-one (100 mg, 0.47 mmol) and 4-fluorobenzoic acid (98 mg, 0.7 mmol) in DCM (20 mL) was stirred at rt for 5 m in. HATU (269 mg, 0.71 mmol) and DIPEA (183 mg, 1.41 mmol) was added to the re action mixture. After the reaction was completed, the reaction mixture was stirred at rt f or overnight. The reaction mixture was extracted with ethyl acetate (150 mL×2). The organic layer was washed with brine and dried over Na₂SO₄. The solid was filtered off, and the filtrate was concentrated under reduced pressure. The resulting crude product was purified by silica gel chromatography with petroleum ether/ethyl acetate (3/1, v/v) to yield N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-4-fluorobenzamide (90 mg, 57%) as a yellow solid.¹H NMR (400 MHz, CDCl₃) δ 8.20 (s, 1H), 8.03-7.96 (m, 4H), 7.81 (d, J=7.6 Hz, 1H), 7.68 (t, J=7.6 Hz, 1H), 7.20 (t, J=8.4 Hz, 2H), 6.87 (d, J=7.6 Hz, 1H), 3.96 (q, J=7.2 Hz, 2H), 1.37 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 46.¹H NMR (400 MHz, d-DMSO) δ 10.23 (s, 1H), 8.28 (d, J=8.0 Hz, 1H), 8.06 (d, J=6.8 Hz, 1H), 7.83 (t, J=7.6 Hz, 1H), 7.76 (d, J=7.6 Hz, 1H), 7.61-7.26 (m, 4H), 7.16 (d, J=7.6 Hz, 1H), 3.90 (q, J=7.2 Hz, 2H), 3.82 (s, 2H), 1.25 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 46.¹H NMR (400 MHz, CDCl₃) δ 8.01 (d, J=6.8 Hz, 1H), 7.87 (d, J=7.6 Hz, 1H), 7.62 (t, J=7.6 Hz, 1H), 7.55 (s, 1H), 7.50 (d, J=8.0 Hz, 1H), 6.98-6.94 (m, 3H), 6.85 (d, J=7.6 Hz, 1H), 3.96-3.92 (m, 8H), 3.82 (s, 2H), 1.34 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 46.¹H NMR (400 MHz, d-DMSO) δ 10.29 (s, 1H), 8.33 (d, J=8.0 Hz, 1H), 8.07 (d, J=6.8 Hz, 1H), 7.84 (t, J=7.6 Hz, 1H), 7.74 (d, J=7.6 Hz, 1H), 7.63 (s, 1H), 7.52 (d, J=8.4 Hz, 1H), 7.43 (d, J=8.4 Hz, 1H), 7.17 (d, J=7.6 Hz, 1H), 4.01 (s, 2H), 3.91 (q, J=7.2 Hz, 2H), 1.26 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 46.¹H NMR (400 MHz, d-DMSO) δ 9.95 (s, 1H), 8.11 (d, J=8.4 Hz, 1H), 8.05 (d, J=7.2 Hz, 1H), 7.86-7.73 (m, 1H), 7.71 (d, J=7.6 Hz, 1H), 7.31 (d, J=4.0 Hz, 3H), 7.23 (s, 1H), 7.16 (d, J=7.6 Hz, 1H), 3.91 (q, J=7.2 Hz, 2H), 2.98 (t, J=7.6 Hz, 2H), 2.79 (t, J=7.6 Hz, 2H), 1.26 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 46.¹H NMR (400 MHz, d-DMSO) δ 10.14 (s, 1H), 8.32 (d, J=8.4 Hz, 1H), 8.07 (d, J=6.8 Hz, 1H), 7.83 (t, J=7.6 Hz, 1H), 7.77 (d, J=7.6 Hz, 1H), 7.18 (d, J=7.6 Hz, 1H), 3.91 (q, J=7.2 Hz, 2H), 2.88-2.71 (m, 2H), 2.71-2.51 (m, 2H), 1.26 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 46.¹H NMR (400 MHz, d-DMSO) δ 9.92 (s, 1H), 8.30 (d, J=8.4 Hz, 1H), 8.06 (d, J=6.8 Hz, 1H), 7.89-7.62 (m, 2H), 7.16 (d, J=7.6 Hz, 1H), 3.91 (q, J=7.2 Hz, 2H), 2.46 (q, J=7.6 Hz, 2H), 1.26 (t, J=7.2 Hz, 3H), 1.16 (t, J=7.6 Hz, 3H).

The synthesis can refer to Example 46.¹H NMR (400 MHz, d-DMSO) δ 10.55 (s, 1H), 8.20 (d, J=8.0 Hz, 1H), 8.09 (t, J=8.8 Hz, 3H), 7.81 (t, J=7.6 Hz, 1H), 7.65 (d, J=8.4 Hz, 3H), 7.23 (d, J=7.6 Hz, 1H), 3.94 (q, J=7.2 Hz, 2H), 1.29 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 46.¹H NMR (400 MHz, d-DMSO) d 10.19 (s, 1H), 8.27 (d, J=8.0 Hz, 1H), 8.06 (d, J=6.8 Hz, 1H), 7.82 (t, J=7.6 Hz, 1H), 7.75 (d, J=7.6 Hz, 1H), 7.30 (d, J=7.6 Hz, 2H), 7.16 (d, J=7.6 Hz, 3H), 3.90 (q, J=7.2 Hz, 2H), 3.75 (s, 2H), 2.29 (s, 3H), 1.25 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 46.¹H NMR (400 MHz, d-DMSO) δ 10.24 (s, 1H), 8.43 (d, J=8.0 Hz, 1H), 8.07 (t, J=7.6 Hz, 2H), 7.84 (d, J=11.2 Hz, 2H), 7.45 (d, J=11.2 Hz, 1H), 7.20 (d, J=7.6 Hz, 1H), 7.04-6.75 (m, 2H), 6.64 (s, 1H), 3.92 (q, J=6.8 Hz, 2H), 1.27 (t, J=7.2 Hz, 3H).

The synthesis of formula III:

6-amino-1-ethylbenzo[cd]indol-2(1H)-one can refer to Example 1.

A reaction mixture of 6-amino-1-ethylbenzo[cd]indol-2(1H)-one (100 mg, 0.47 mmol) and (3-chloropropyl)benzene (73 mg, 0.47 mmol) in CH₃CN (20 mL) was stirred at rt. K₂CO₃ (195 mg, 1.41 mmol) was added to the reaction mixture, and stirred at 70° C. for overnight. The reaction mixture was extracted with ethyl acetate (150 mL×2). The organic layer was washed with brine and dried over Na₂SO₄. The solid was filtered off, and the filtrate was concentrated under reduced pressure. The resulting crude product was purified by silica gel chromatography with petroleum ether/ethyl acetate (5/1, v/v) to yield 1-ethyl-6-((3-phenylpropyl)amino)benzo[cd]indol-2(1H)-one (60 mg, 38%) as a yellow solid.¹H NMR (400 MHz, CDCl₃) δ 8.06 (d, J=7.2 Hz, 11H), 7.84 (d, J=8.0 Hz, 1H), 7.63 (t, J=7.6 Hz, 1H), 7.32 (t, J=7.6 Hz, 2H), 7.26-7.04 (m, 3H), 6.77 (d, J=7.6 Hz, 1H), 6.34 (d, J=7.2 Hz, 1H), 4.24 (s, 1H), 3.94 (q, J=7.2 Hz, 2H), 3.30 (t, J=6.8 Hz, 2H), 2.83 (t, J=7.2 Hz, 2H), 2.21-2.03 (m, 2H), 1.36 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 56.¹H NMR (400 MHz, CDCl₃) δ 8.07 (d, J=7.6 Hz, 2H), 7.66 (t, J=7.6 Hz, 1H), 6.79 (d, J=7.6 Hz, 1H), 6.35 (d, J=7.6 Hz, 1H), 5.81 (s, 1H), 3.95 (q, J=7.2 Hz, 2H), 3.82 (t, J=4.4 Hz, 4H), 3.35 (t, J=6.0 Hz, 2H), 2.60-2.54 (m, 6H), 2.02-1.87 (m, 2H), 1.36 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 56.¹H NMR (400 MHz, d-DMSO) δ 8.51 (d, J=8.0 Hz, 1H), 7.98 (d, J=7.2 Hz, 1H), 7.71 (t, J=7.6 Hz, 1H), 7.33 (d, J=8.4 Hz, 2H), 7.05 (s, 1H), 6.88 (d, J=8.4 Hz, 3H), 6.21 (d, J=7.6 Hz, 1H), 4.40 (d, J=4.4 Hz, 2H), 3.82 (q, J=7.2 Hz, 2H), 3.70 (d, J=8.8 Hz, 3H), 1.20 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 56.¹H NMR (400 MHz, d-DMSO) δ 8.52 (d, J=8.0 Hz, 1H), 7.99 (d, J=6.8 Hz, 1H), 7.71 (t, J=7.6 Hz, 1H), 7.29 (d, J=7.6 Hz, 2H), 7.12 (d, J=7.6 Hz, 3H), 6.87 (d, J=7.6 Hz, 1H), 6.17 (d, J=7.6 Hz, 1H), 4.42 (s, 2H), 3.81 (q, J=7.2 Hz, 2H), 2.26 (s, 3H), 1.20 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 56.¹H NMR (400 MHz, d-DMSO) δ 8.52 (d, J=8.0 Hz, 1H), 8.00 (d, J=6.8 Hz, 1H), 7.74 (t, J=7.6 Hz, 1H), 7.69 (d, J=8.0 Hz, 2H), 7.63 (d, J=8.0 Hz, 2H), 7.26 (s, 1H), 6.87 (d, J=7.6 Hz, 1H), 6.14 (d, J=7.6 Hz, 1H), 4.58 (d, J=5.2 Hz, 2H), 3.81 (q, J=7.2 Hz, 2H), 1.20 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 56.¹H NMR (400 MHz, d-DMSO) δ 8.51 (d, J=8.4 Hz, 1H), 8.00 (d, J=6.8 Hz, 1H), 7.73 (t, J=7.6 Hz, 1H), 7.43 (d, J=8.4 Hz, 2H), 7.37 (d, J=8.4 Hz, 2H), 7.18 (t, J=6.0 Hz, 1H), 6.88 (d, J=7.6 Hz, 1H), 6.15 (d, J=7.6 Hz, 1H), 4.47 (d, J=6.0 Hz, 2H), 3.82 (q, J=7.2 Hz, 2H), 1.20 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 56.¹H NMR (400 MHz, CDCl₃) δ 8.07 (d, J=7.2 Hz, 1H), 8.00 (d, J=8.2 Hz, 1H), 7.66 (t, J=7.6 Hz, 1H), 7.41 (dd, J=8.4, 5.6 Hz, 2H), 7.06 (t, J=8.4 Hz, 2H), 6.75 (d, J=7.6 Hz, 1H), 6.38 (d, J=7.6 Hz, 1H), 4.66 (s, 1H), 4.45 (s, 2H), 3.94 (q, J=7.2 Hz, 2H), 1.35 (t, J=7.2 Hz, 3H).

The synthesis of formula IV:

The synthesis of 1-ethylbenzo[cd]indol-2(1H)-one can refer to Example 1.

To a solution of 1-ethylbenzo[cd]indol-2(1H)-one (6.46 g, 0.03 mol) in chloroform (100 mL) was added batches of chlorosulfonic (11.5 g, 0.1 mol) at 0° C. for 10 min. The reaction mixture was heated at 50° C. for 6 h. The mixture was then poured into ice water and extracted with DCM (150 mL×2). The organic layer was washed with brine and dried over Na₂SO₄. The solid was filtered off, and the filtrate was concentrated under reduced pressure. The resulting crude product was purified by silica gel chromatography with petroleum ether/ethyl acetate (5/1, v/v) to yield 1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonyl chloride (5.75 g, 59%) as a yellow solid. MS (ESI), m/z: M⁺ 297.1.

A reaction mixture of 1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonyl chloride (100 mg, 0.34 mmol) and 1-(4-(aminomethyl)piperidin-1-yl)ethan-1-one (64 mg, 0.41 mmol) in pyridine (5 mL) was stirred at 80° C. for 1 h. Dilute HCl was added, the aqueous layer was extracted with ethyl acetate (50 mL×3), and the organic layer was washed with water and brine, dried with Na₂SO₄ and evaporated. The residue was purified by silica gel chromatography with petroleum and ether/ethyl acetate (4/1, v/v) to afford N-((1-acetylpiperidin-4-yl)methyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide (92 mg, 65%).¹H-NMR (400 MHz, d-DMSO) δ 8.69 (d, J=8.4 Hz, 1H), 8.16 (d, J=6.8 Hz, 1H), 8.07 (d, J=7.6 Hz, 1H), 7.96 (t, J=7.2 Hz, 1H), 7.86 (t, J=6.0 Hz, 1H), 7.31 (d, J=7.6 Hz, 1H), 4.24 (d, J=8.0 Hz, 1H), 3.93 (q, J=6.8 Hz, 2H), 3.69 (d, J=12.4 Hz, 1H), 2.87 (t, J=13.2 Hz, 1H), 2.64 (t, J=6.0 Hz, 2H), 2.36 (t, J=12.0 Hz, 1H). 1.92 (s, 3H), 1.56-1.51 (m, 3H), 1.28 (t, J=7.2 Hz, 3H). MS (ESI), m/z: M⁺ 417.0; M⁻ 415.0.

The synthesis can refer to Example 63.¹H-NMR (400 MHz, d-DMSO) d 8.58 (d, J=8.4 Hz, 1H), 8.15 (d, J=7.2 Hz, 1H), 8.09 (d, J=7.6 Hz, 1H), 7.96 (t, J=8.0 Hz, 1H), 7.31 (d, J=7.6 Hz, 1H), 3.92 (q, J=6.8 Hz, 2H), 3.26-3.21 (m, 4H), 1.25 (t, J=7.2 Hz, 3H), 1.01-0.98 (m, 6H). MS (ESI), m/z: M⁻ 400.8.

The synthesis can refer to Example 63.¹H-NMR (400 MHz, d-DMSO) δ 8.70 (d, J=8.0 Hz, 1H), 8.14-8.09 (m, 2H), 8.06 (d, J=7.6 Hz, 1H), 7.94 (t, J=7.6 Hz, 1H), 7.29 (d, J=7.2 Hz, 1H), 4.43-4.39 (m, 1H), 3.93 (q, J=6.8 Hz, 2H), 2.84-2.83 (m, 2H), 2.48 (s, 3H), 1.26 (t, J=6.8 Hz, 1H), 0.98 (s, 6H). MS (ESI), m/z: M⁻ 400.0.

The synthesis can refer to Example 63.¹H-NMR (400 MHz, d-DMSO) δ 8.72 (d, J=8.4 Hz, 1H), 8.15-8.10 (m, 2H), 8.07 (d, J=7.6 Hz, 1H), 7.94 (t, J=7.2 Hz, 1H), 7.30 (d, J=7.6 Hz, 1H), 3.93 (q, J=7.2 Hz, 2H), 2.85-2.82 (m, 3H), 2.58 (s, 1H), 1.75 (s, 3H), 1.27-1.22 (m, 4H), 1.17 (s, 2H). MS (ESI), m/z: M⁻ 386.0.

The synthesis of 1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonyl chloride can refer to Example 63.

A reaction mixture of I-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonyl chloride (100 mg, 0.34 mmol) and 1-(4-aminophenyl)ethan-1-one (55 mg, 0.41 mmol) in pyridine (3 m L) was stirred at rt for overnight. Dilute HCl was added, the aqueous layer was extracted with ethyl acetate (50 mL×3), and the organic layer was washed with water and brine, dried with Na₂SO₄ and evaporated. The residue was purified by silica gel chromatography with petroleum and ether/ethyl acetate (4/1, v/v) to afford N-((1-acetylpiperidin-4-yl)methyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide (80 mg, 60%).¹H-NMR (400 MHz, d-DMSO) δ10.82 (s, 1H), 8.69 (d, J=8.4 Hz, 1H), 8.19 (d, J=7.6 Hz, 1H), 8.09 (d, J=7.2 Hz, 1H), 7.94 (t, J=8.0 Hz, 1H), 7.58-7.53 (m, 2H), 7.31 (d, J=5.6 Hz, 2H), 7.25 (d, J=7.6 Hz, 1H), 3.86 (q, J=6.8 Hz, 2H), 2.43 (s, 3H), 1.22 (t, J=6.8 Hz, 3H). MS (ESI), m/z: M+395.0; M⁻393.0.

The synthesis can refer to Example 63.¹H-NMR (400 MHz, d-DMSO) δ 8.68 (d, J=8.0 Hz, 1H), 8.13 (d, J=7.2 Hz, 1H), 8.04 (d, J=7.6 Hz, 1H), 7.92 (t, J=7.2 Hz, 1H), 7.27-7.29 (m, 3H), 7.12-7.02 (m, 2H), 4.12 (s, 2H), 3.93 (q, J=7.2 Hz, 1H), 1.27 (t, J=7.2 Hz, 3H). MS (ESI), m/z: M⁻ 399.0.

The synthesis can refer to Example 63.¹H-NMR (400 MHz, d-DMSO) δ 8.64 (d, J=8.4 Hz, 1H), 8.41 (s, 1H), 8.12 (d, J=6.8 Hz, 1H), 8.03 (d, J=8.0 Hz, 1H), 7.91 (t, J=7.2 Hz, 1H), 7.21 (d, J=7.6 Hz, 1H), 7.15 (t, J=8.0 Hz, H), 7.07-7.05 (m, 1H), 7.91-7.83 (m, 2H), 4.06 (s, 2H), 3.92 (q, J=7.2 Hz, 2H), 1.29 (t, J=7.2 Hz, 3H). MS (ESI), m/z: M⁻ 383.0.

The synthesis can refer to Example 63.¹H-NMR (400 MHz, d-DMSO) δ 8.70 (d, J=8.4 Hz, 1H), 8.16-8.11 (m, 2H), 8.02 (d, J=7.6 Hz, 1H), 7.94 (q, J=7.2 Hz, 1H), 7.30 (d, J=8.0 Hz, 1H), 4.01 (q, J=6.8 Hz, 1H), 3.93 (q, J=7.2 Hz, 2H), 3.58 (d, J=14.0 Hz, 1H), 3.33-3.19 (m, 1H), 2.97-2.90 (m, 1H), 2.62-2.55 (m, 1H), 1.88 (s, 3H), 1.49 (d, J=10.0 Hz, 2H), 1.28 (t, J=7.2 Hz, 3H), 1.27-1.22 (m, 2H). MS (ESI), m/z: M⁺ 402.1; M⁻ 400.1.

The synthesis can refer to Example 63.¹H-NMR (400 MHz, d-DMSO) δ 8.68 (d, J=8.4 Hz, 1H), 8.15-8.10 (m, 2H), 7.98-7.92 (m, 2H), 7.29 (d, J=7.6 Hz, 1H), 3.93 (d, J=7.2 Hz, 2H), 3.67-3.64 (m, 2H), 3.18 (s, 1H), 2.69 (s, 2H), 1.47-1.44 (m, 2H), 1.32 (s, 9H), 1.32-1.25 (m, 3H), 1.17-1.51 (m, 2H). MS (ESI), m/z: M 458.0.

The synthesis can refer to Example 63.¹H-NMR (400 MHz, d-DMSO) δ 8.72 (d, J=8.4 Hz, 1H), 8.14 (d, J=6.8 Hz, 1H), 8.09 (d, J=7.6 Hz, H), 7.95 (t, J=7.6 Hz, 1H), 7.80 (d, J=7.2 Hz, 1H), 7.26 (d, J=7.6 Hz, 1H), 3.95 (q, J=7.2 Hz, 2H), 3.44 (q, J=6.4 Hz, 1H), 1.51-1.46 (m, 4H), 1.28-1.22 (m, 7H). MS (ESI), m/z: M 343.0.

The synthesis can refer to Example 63.¹H-NMR (400 MHz, d-DMSO) δ 8.63 (d, J=8.4 Hz, 1H), 8.17 (d, J=7.6 Hz, 1H), 8.11 (d, J=7.2 Hz, 1H), 7.86 (t, J=8.0 Hz, 1H), 6.93 (d, J=7.6 Hz, 1H), 5.36 (t, J=6.8 Hz, 1H), 4.04-3.96 (m, 4H), 2.92 (d, J=7.2 Hz, 2H), 1.93-1.89 (m, 2H), 1.71 (s, 2H), 1.58-1.54 (m, 6H), 1.39 (t, J=7.2 Hz, 3H), 1.16 (t, J=7.2 Hz, 3H). MS (ESI), m/z: M⁻ 429.0.

The synthesis of ethyl 1-((1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)meth yl)cyclopentanecarboxylate can refer to Example 73.

Ethyl1-((1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)methyl)cyclopentanecarboxylate (100 mg, 0.23 mmol) was dissolved in THF (5 mL) and 2 mol/L NaOH aqueous solution (5 mL). The mixture was stirred at room temperature for 2 h. The solvent w as removed and diluted hydrochloric acid was added dropwise, and a yellow precipitate was formed. The precipitate was collected by filtration and washed with water (10 mL×2). The resulting crude product was purified by recrystallization with petroleum and ether/ethyl acetate to afford 1-((1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)methyl)cyclopentanecarboxylic acid (86 mg, 93%) as a yellow solid.¹H-NMR (400 MHz, d-DMSO) δ 8.63 (d, J=8.4 Hz, 1H), 8.17 (d, J=7.6 Hz, 1H), 8.11 (d, J=7.2 Hz, 1H), 7.86 (t, J=8.0 Hz, 1H), 6.93 (d, J=7.6 Hz, 1H), 5.36 (t, J=6.8 Hz, 1H), 3.92 (m, 3H), 2.83 (s, 2H), 1.81 (m, 2H), 1.45 (m, 6H), 1.25 (m, 4H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, d-DMSO) δ 10.33 (s, 1H), 9.79 (s, 1H), 8.68 (d, J=8.0 Hz, 1H), 8.10 (dd, J=14.4, 6.8 Hz, 2H), 7.92 (t, J=7.2 Hz, 1H), 7.34 (d, J=7.6 Hz, 2H), 7.23 (d, J=7.6 Hz, 1H), 6.94 (d, J=7.6 Hz, 2H), 3.88 (d, J=6.8 Hz, 2H), 1.95 (s, 3H), 1.23 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 74.¹H NMR (400 MHz, d-DMSO) δ 11.96 (s, 1H), 8.52 (d, J=8.4 Hz, 1H), 8.26 (d, J=7.6 Hz, 1H), 8.13 (d, J=7.2 Hz, 1H), 8.02-7.84 (m, 1H), 7.80 (d, J=7.2 Hz, 1H), 7.63-7.41 (m, 2H), 7.28 (d, J=7.6 Hz, 1H), 7.02 (t, J=7.6 Hz, 1H), 3.89 (q, J=7.2 Hz, 2H), 1.23 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, d-DMSO) δ 10.48 (s, 1H), 8.64 (d, J=8.4 Hz, 1H), 8.13-8.07 (m, 2H), 8.00-7.79 (m, 1H), 7.25 (d, J=7.6 Hz, 1H), 7.17-6.83 (m, 4H), 3.89 (q, J=7.2 Hz, 2H), 1.25 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, d-DMSO) δ 8.69 (d, J=8.4 Hz, 1H), 8.15 (d, J=7.2 Hz, 1H), 8.08 (d, J=7.6 Hz, 1H), 8.01-7.85 (m, 1H), 7.77 (t, J=6.0 Hz, 1H), 7.31 (d, J=7.6 Hz, 1H), 3.94 (q, J=7.2 Hz, 2H), 2.75 (dd, J=13.2, 6.8 Hz, 2H), 1.35-1.21 (m, 5H), 1.19-1.12 (m, 2H), 0.70 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, d-DMSO) δ 8.65 (d, J=8.2 Hz, 1H), 8.14 (d, J=6.4 Hz, 1H), 8.06 (d, J=7.2 Hz, 1H), 7.94 (t, J=7.2 Hz, 1H), 7.87 (s, 1H), 7.76 (s, 1H), 7.30 (d, J=7.2 Hz, 1H), 3.93 (d, J=6.8 Hz, 2H), 3.01 (d, J=5.6 Hz, 2H), 2.77 (s, 2H), 1.65 (s, 3H), 1.26 (t, J=6.4 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, d-DMSO) δ 8.64 (d, J=8.4 Hz, 1H), 8.16-8.10 (m, 3H), 7.96 (t, J=7.6 Hz, 1H), 7.33 (d, J=7.6 Hz, 1H), 3.94 (q, J=6.8 Hz, 2H), 3.23 (t, J=6.8 Hz, 2H), 3.14 (t, J=6.8 Hz, 2H), 2.97 (s, 3H), 1.27 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, d-DMSO) δ 8.66 (d, J=8.0 Hz, 1H), 8.14 (d, J=6.4 Hz, 1H), 8.08 (d, J=7.2 Hz, 1H), 7.92 (d, J=6.4 Hz, 2H), 7.29 (d, J=7.2 Hz, 1H), 6.23 (s, 1H), 3.93 (d, J=6.4 Hz, 2H), 3.18 (d, J=7.2 Hz, 2H), 3.09-3.02 (m, 4H), 2.86-2.84 (m, 2H), 1.26 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, d-DMSO) δ 8.67 (d, J=8.4 Hz, 1H), 8.13 (d, J=6.8 Hz, 1H), 8.06 (d, J=7.6 Hz, 1H), 7.93 (t, J=7.6 Hz, 1H), 7.76 (s, 1H), 7.29 (d, J=7.6 Hz, 1H), 6.67 (s, 1H), 3.92 (d, J=7.2 Hz, 2H), 2.91-2.64 (m, 4H), 1.26 (s, 9H), 1.25-1.24 (m, 4H), 1.24 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, d-DMSO) δ 10.48 (s, 1H), 10.34 (s, 1H), 8.62 (d, J=8.4 Hz, 1H), 8.12 (d, J=7.6 Hz, 1H), 8.06 (d, J=7.6 Hz, 1H), 7.99-7.70 (m, 3H), 7.41 (d, J=8.8 Hz, 1H), 7.23 (d, J=7.6 Hz, 1H), 3.88 (q, J=6.8 Hz, 2H), 1.98 (d, J=8.4 Hz, 3H), 1.22 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, CDCl₃) δ 8.62 (d, J=8.4 Hz, 1H), 8.23 (d, J=7.6 Hz, 1H), 8.13 (d, J=7.2 Hz, 1H), 7.85 (t, J=7.6 Hz, 1H), 6.95 (d, J=7.6 Hz, 1H), 5.10 (d, J=7.2 Hz, 1H), 4.00 (q, J=7.2 Hz, 2H), 3.86 (d, J=4.8 Hz, 1H), 3.48-3.30 (m, 2H), 3.29-3.26 (m, 1H), 3.07-3.03 (m, 1H), 1.94-1.87 (m, 2H), 1.48-1.29 (m, 12H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, CDCl₃) δ 8.60 (d, J=8.4 Hz, 1H), 8.14 (d, J=7.6 Hz, 1H), 8.12 (d, J=6.8 Hz, 1H) 7.85 (t, J=7.6 Hz, 1H), 6.92 (d, J=7.6 Hz, 1H), 5.31 (d, J=8.8 Hz, 1H), 4.11 (d, J=8.0 Hz, 1H), 4.01-3.95 (m, 4H), 3.56 (s, 2H), 1.44-1.30 (m, 12H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, CDCl₃) δ 8.64 (d, J=8.4 Hz, 1H), 8.19 (d, J=7.6 Hz, 1H), 8.12 (d, J=7.2 Hz, 1H), 7.84 (t, J=7.2 Hz, 1H), 6.93 (d, J=7.5 Hz, 1H), 4.41 (t, J=6.0 Hz, 1H), 3.99 (q, J=7.2 Hz, 2H), 2.97 (dd, J=13.2, 6.8 Hz, 2H), 1.39-1.37 (m, 4H), 1.28-1.25 (m, 6H), 1.13-1.08 (m, 2H), 1.02-0.97 (m, 2H), 0.96-0.89 (m, 2H).

The synthesis of tert-butyl3-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido) pyrrolidine-1-carboxylate can refer to 84.

Tert-butyl3-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)pyrrolidine-1-carboxylate (50 mg, 0.112 mmol) was dissolved in DCM (20 mL) and trifluoroacetic acid (0.5 mL). The mixture was stirred at room temperature for 2 h. The solvent was removed and was purified by recrystallization with petroleum and ether/ethyl acetate to afford 1-ethyl-2-oxo-N-(pyrrolidin-3-yl)-1,2-dihydrobenzo[cd]indole-6-sulfonamide (37 mg, 95%) as a yellow solid.¹H NMR (400 MHz, d-DMSO) δ 8.74 (s, 1H), 8.65 (d, J=8.4 Hz, 1H), 8.29 (d, J=6.0 Hz, 1H), 8.18 (d, J=7.2 Hz, 1H), 8.13 (d, J=7.6 Hz, 1H), 8.03-7.86 (m, 1H), 7.34 (d, J=7.6 Hz, 1H), 3.94 (q, J=7.2 Hz, 1H), 3.74 (dd, J=12.0, 6.0 Hz, 1H), 3.18-3.12 (m, 1H), 3.11-2.99 (m, 1H), 2.93-2.89 (m, 1H), 1.90-1.83 (m, 1H), 1.69-1.66 (m, 1H), 1.27 (t, J=7.2 Hz, 2H).

The synthesis can refer to Example 87.¹H NMR (400 MHz, d-DMSO) δ 8.78 (d, J=7.6 Hz, 1H), 8.61 (d, J=8.4 Hz, 2H), 8.18 (d, J=7.2 Hz, 1H), 8.10 (d, J=7.6 Hz, 1H), 7.99 (t, 7.2 Hz, 1H), 7.33 (d, J=7.6 Hz, 1H), 3.94 (q, J=7.2 Hz, 2H), 3.86 (t, J=9.2 Hz, 2H), 3.66 (s, 2H), 1.27 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, d-DMSO) δ 8.68 (d, J=8.4 Hz, 1H), 8.14 (d, J=7.2 Hz, 1H), 8.07 (d, J=7.6 Hz, 1H), 8.00-7.83 (m, 1H), 7.76 (t, J=6.0 Hz, 1H), 7.29 (d, J=7.6 Hz, 1H), 3.93 (q, J=7.2 Hz, 2H), 2.75 (dd, J=12.8, 6.4 Hz, 2H), 1.35-1.12 (m, 6H), 1.09-0.88 (m, 6H), 0.67 (t, J=6.8 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, d-DMSO) δ 8.68 (d, J=8.2 Hz, 1H), 8.17 (d, J=6.8 Hz, 1H), 8.12 (d, J=7.6 Hz, 1H), 7.96 (t, J=7.6 Hz, 1H), 7.33 (d, J=7.6 Hz, 1H), 4.00-3.88 (m, 2H), 3.18-3.02 (m, 3H), 2.85 (s, 4H), 1.73 (s, 3H), 1.28 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, d-DMSO) δ 8.69 (d, J=8.4 Hz, 1H), 8.16 (d, J=7.2 Hz, 1H), 8.08 (d, J=7.6 Hz, 1H), 7.96 (t, J=7.6 Hz, 1H), 7.78 (s, 1H), 7.30 (d, J=7.6 Hz, 1H), 3.93 (t, J=7.2 Hz, 2H), 3.63 (dd, J=11.2, 3.6 Hz, 2H), 2.89 (t, J=11.2 Hz, 2H), 2.80 (d, J=4.8 Hz, 2H), 1.35-1.10 (m, 8H), 0.90-0.86 (m, 2H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, d-DMSO) δ 8.69 (d, J=8.4 Hz, 1H), 8.16 (d, J=6.0 Hz, 2H), 8.11 (d, J=7.6 Hz, 1H), 7.95 (t, J=7.6 Hz, 1H), 7.32 (d, J=7.6 Hz, 1H), 3.94 (q, J=7.2 Hz, 2H), 3.72 (s, 1H), 3.64 (dd, J=14.4, 7.2 Hz, 1H), 3.59-3.44 (m, 2H), 1.81-1.76 (m, 1H), 1.53 (dd, J=12.4, 6.0 Hz, 1H), 1.27 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, CDCl₃) δ 8.61 (d, J=8.4 Hz, 1H), 8.19 (d, J=7.6 Hz, 1H), 8.09 (d, J=7.2 Hz, 1H), 7.82 (t, J=7.6 Hz, 1H), 7.10 (d, J=8.8 Hz, 2H), 6.88 (d, J=7.6 Hz, 1H), 6.51 (d, J=8.8 Hz, 2H), 5.08 (t, J=6.0 Hz, 1H), 3.97 (q, J=7.2 Hz, 2H), 3.88 (t, J=5.2 Hz, 2H), 3.37 (dd, J=10.8, 5.2 Hz, 2H), 1.38 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, CDCl₃) δ 8.65 (d, J=8.4 Hz, 1H), 8.20 (d, J=7.6 Hz, 1H), 8.12 (d, J=6.8 Hz, 1H), 7.84 (t, J=7.6 Hz, 1H), 6.93 (d, J=7.6 Hz, 1H), 4.52 (s, 1H), 3.99 (q, J=7.2 Hz, 2H), 3.02 (t, J=7.2 Hz, 2H), 1.39 (t, J=7.2 Hz, 3H), 1.08 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, CDCl₃) δ 8.64 (d, J=8.4 Hz, 1H), 8.18 (d, J=7.6 Hz, 1H), 8.11 (d, J=6.8 Hz, 1H), 7.84 (t, J=7.6 Hz, 1H), 6.92 (d, J=7.6 Hz, 1H), 4.54 (d, J=6.0 Hz, 1H), 3.99 (q, J=7.2 Hz, 2H), 2.94 (q, J=6.8 Hz, 2H), 1.40 (q, J=7.2 Hz, 5H), 1.16 (d, J=6.4 Hz, 4H), 0.75 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, CDCl₃) δ 8.64 (d, J=8.4 Hz, 1H), 8.19 (d, J=7.6 Hz, 1H), 8.12 (d, J=7.2 Hz, 1H), 7.83 (t, J=7.6 Hz, 1H), 6.94 (d, J=7.6 Hz, 1H), 4.49 (d, J=5.2 Hz, 1H), 3.99 (q, J=7.2 Hz, 2H), 2.65 (d, J=5.2 Hz, 3H), 1.39 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, CDCl₃) δ 8.61 (d, J=8.4 Hz, 1H), 8.20 (d, J=7.6 Hz, 1H), 8.11 (d, J=7.2 Hz, 1H), 7.84 (t, J=7.2 Hz, 1H), 6.92 (d, J=7.6 Hz, 1H), 4.52 (d, J=7.6 Hz, 1H), 3.99 (q, J=7.2 Hz, 2H), 3.29-2.92 (m, 1H), 1.75-1.63 (m, 2H), 1.58-1.50 (m, 1H), 1.49-1.46 (m, 1H), 1.40 (t, J=7.2 Hz, 3H), 1.25-1.05 (m, 6H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, CDCl₃) δ 8.60 (d, J=8.4 Hz, 1H), 8.21 (d, J=7.6 Hz, 1H), 8.11 (d, J=7.2 Hz, 1H), 7.84 (t, J=7.6 Hz, 1H), 6.92 (d, J=7.6 Hz, 1H), 4.87 (s, 1H), 3.98 (q, J=7.2 Hz, 2H), 3.47-3.16 (m, 4H), 3.02 (dd, J=13.2, 7.2 Hz, 1H), 1.67-1.53 (m, 2H), 1.47-1.25 (m, 14H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, CDCl₃) δ 8.64 (d, J=8.4 Hz, 1H), 8.18 (d, J=7.6 Hz, 1H), 8.11 (d, J=7.2 Hz, 1H), 7.84 (t, J=7.6 Hz, 1H), 6.92 (d, J=7.6 Hz, 1H), 4.61 (t, J=6.4 Hz, 1H), 3.99 (q, J=7.2 Hz, 2H), 2.75 (t, J=6.4 Hz, 2H), 1.67 (dt, J=13.2, 6.8 Hz, 1H), 1.39 (t, J=7.2 Hz, 3H), 0.81 (d, J=6.8 Hz, 6H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, CDCl₃) δ 8.65 (d, J=8.4 Hz, 1H), 8.18 (d, J=7.6 Hz, 1H), 8.10 (d, J=7.2 Hz, 1H), 7.92-7.68 (m, 1H), 6.92 (d, J=7.6 Hz, 1H), 4.66 (t, J=6.0 Hz, 1H), 3.98 (q, J=7.2 Hz, 2H), 2.91 (dd, J=13.2, 6.8 Hz, 2H), 1.46 (dt, J=14.4, 7.2 Hz, 2H), 1.39 (t, J=7.2 Hz, 3H), 0.80 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, d-DMSO) δ 8.68 (d, J=8.4 Hz, 1H), 8.16 (d, J=6.8 Hz, 1H), 8.08 (d, J=7.2 Hz, 1H), 7.95 (t, J=7.6 Hz, 1H), 7.78 (s, 1H), 7.31 (d, J=7.6 Hz, 1H), 3.94 (q, J=7.2 Hz, 2H), 2.79 (d, J=5.6 Hz, 2H), 2.23-1.86 (m, 11H), 1.48-1.33 (m, 2H), 1.28 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, d-DMSO) δ 8.68 (d, J=8.4 Hz, 1H), 8.15 (d, J=6.8 Hz, 1H), 8.10 (d, J=7.6 Hz, 1H), 7.94 (t, J=7.6 Hz, 1H), 7.67 (s, 1H), 7.30 (d, J=7.6 Hz, 1H), 3.94 (q, J=7.2 Hz, 2H), 2.88 (t, J=6.4 Hz, 2H), 2.23-2.11 (m, 2H), 2.10-2.01 (m, 3H), 1.30-1.22 (m, 7H), 0.94-0.65 (m, 2H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, d-DMSO) δ 8.67 (d, J=8.4 Hz, 1H), 8.14 (d, J=6.8 Hz, 1H), 8.06 (d, J=7.6 Hz, 1H), 7.93 (t, J=7.6 Hz, 1H), 7.79 (t, J=5.2 Hz, 1H), 7.29 (d, J=7.6 Hz, 1H), 4.18 (s, 1H), 3.92 (q, J=6.8 Hz, 2H), 3.42-3.31 (m, 2H), 3.23-3.17 (m, 2H), 2.78 (d, J=5.2 Hz, 2H), 1.35-1.21 (m, 7H), 0.95 (t, J=6.8 Hz, 6H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, CDCl₃) δ 8.61 (d, J=8.4 Hz, 1H), 8.19 (d, J=7.6 Hz, 1H), 8.12 (d, J=7.2 Hz, 1H), 7.96-7.69 (m, 1H), 6.93 (d, J=7.6 Hz, 1H), 5.35 (t, J=6.4 Hz, 1H), 4.01-3.96 (m, 4H), 3.19 (dd, J=12.4, 6.4 Hz, 2H), 2.48 (t, J=6.0 Hz, 2H), 1.39 (t, J=7.2 Hz, 3H), 1.18 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, CDCl₃) δ 8.68 (d, J=8.4 Hz, 1H), 8.12 (dd, J=10.4, 7.2 Hz, 2H), 7.96-7.78 (m, 1H), 6.90 (d, J=7.6 Hz, 1H), 3.98 (q, J=7.2 Hz, 2H), 3.67 (d, J=5.6 Hz, 1H), 3.46 (s, 1H), 3.37 (dd, J=14.4, 7.6 Hz, 2H), 3.19 (dd, J=14.4, 3.2 Hz, 1H), 2.87 (s, 1H), 2.76 (s, 1H), 2.15-1.80 (m, 5H), 1.38 (t, J=7.2 Hz, 6H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, d-DMSO) δ 8.68 (d, J=8.4 Hz, 1H), 8.14 (d, J=7.2 Hz, 1H), 8.09 (d, J=7.6 Hz, 1H), 7.93 (dd, J=12.4, 5.6 Hz, 2H), 7.29 (d, J=7.6 Hz, 1H), 3.93 (q, J=7.2 Hz, 2H), 2.93 (s, 1H), 2.58 (d, J=11.2 Hz, 2H), 2.06 (s, 3H), 1.82 (s, 2H), 1.44 (d, J=10.4 Hz, 2H), 1.38-1.35 (m, 2H), 1.27 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, CDCl₃) δ 8.63 (d, J=8.4 Hz, 1H), 8.21 (d, J=7.6 Hz, 1H), 8.13 (d, J=7.2 Hz, 1H), 7.93-7.60 (m, 1H), 6.94 (d, J=7.6 Hz, 1H), 4.55 (d, J=8.0 Hz, 1H), 4.01 (q, J=7.2 Hz, 2H), 3.50-3.20 (m, 1H), 1.73-1.69 (m, 2H), 1.55-0.99 (m, 15H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, CDCl₃) δ 8.61 (d, J=8.4 Hz, 1H), 8.21 (d, J=7.6 Hz, 1H), 8.12 (d, J=7.2 Hz, 1H), 7.93-7.77 (m, 1H), 6.92 (d, J=7.6 Hz, 1H), 4.65 (d, J=8.0 Hz, 1H), 3.99 (q, J=7.2 Hz, 2H), 3.82 (d, J=12.0 Hz, 2H), 3.44-3.34 (m, 1H), 3.30 (t, J=10.8 Hz, 2H), 1.69 (d, J=13.2 Hz, 2H), 1.51-1.35 (m, 5H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, CDCl₃) δ 8.63 (d, J=8.4 Hz, 1H), 8.19 (d, J=7.6 Hz, 1H), 8.12 (d, J=7.2 Hz, 1H), 7.93-7.75 (m, 1H), 6.93 (d, J=7.6 Hz, 1H), 5.35 (s, 1H), 3.99 (q, J=7.2 Hz, 2H), 3.28-3.10 (m, 4H), 2.98 (s, 2H), 2.41-2.23 (m, 2H), 2.16-2.04 (m, 4H), 1.47-1.30 (m, 12H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, d-DMSO) δ 8.70 (d, J=8.4 Hz, 1H), 8.14 (d, J=7.6 Hz, 1H), 8.11 (d, J=7.2 Hz, 1H), 8.02-7.89 (m, 1H), 7.85 (d, J=7.6 Hz, 1H), 7.23 (d, J=7.6 Hz, 1H), 3.38 (s, 3H), 2.94 (s, 1H), 1.57-1.33 (m, 5H), 1.04-0.88 (m, 5H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, d-DMSO) δ 8.68 (d, J=8.4 Hz, 1H), 8.15 (d, J=7.2 Hz, 1H), 8.08 (d, J=7.6 Hz, 1H), 7.99-7.83 (m, 1H), 7.77 (s, 1H), 7.25 (d, J=7.6 Hz, 1H), 3.39 (s, 3H), 2.74 (d, J=3.2 Hz, 2H), 1.27 (dd, J=14.8, 7.2 Hz, 2H), 1.15 (dd, J=14.8, 7.2 Hz, 2H), 0.70 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, CDCl₃) δ 8.62 (d, J=8.4 Hz, 1H), 8.18 (d, J=7.2 Hz, 1H), 8.11 (d, J=7.2 Hz, 1H), 7.83 (t, 7.2 Hz, 1H), 6.91 (d, J=7.6 Hz, 1H), 4.57 (d, J=7.6 Hz, 1H), 3.89 (t, J=7.2 Hz, 2H), 3.31-3.03 (m, 1H), 1.82 (dt, J=14.8, 7.2 Hz, 2H), 1.74-1.64 (m, 2H), 1.57-1.56 (m, 2H), 1.48 (d, J=12.4 Hz, 1H), 1.17-1.08 (m, 4H), 1.02 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, CDCl₃) δ 8.64 (d, J=8.4 Hz, 1H), 8.18 (d, J=7.6 Hz, 1H), 8.11 (d, J=7.2 Hz, 1H), 7.94-7.66 (m, 1H), 6.92 (d, J=7.6 Hz, 1H), 4.60 (t, J=6.0 Hz, 1H), 3.89 (t, J=7.2 Hz, 2H), 2.92 (d d, J=13.6, 6.8 Hz, 2H), 1.78 (dt, J=14.4, 7.2 Hz, 2H), 1.44 (dt, J=14.4, 7.2 Hz, 2H), 1.01 (t, J=7.2 Hz, 3H), 0.81 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, CDCl₃) δ 8.64 (d, J=8.4 Hz, 1H), 8.18 (d, J=7.6 Hz, 1H), 8.12 (d, J=7.2 Hz, 1H), 7.84 (dd, J=8.2, 7.2 Hz, 1H), 6.92 (d, J=7.6 Hz, 1H), 4.51 (t, J=6.0 Hz, 1H), 3.90 (t, J=7.2 Hz, 2H), 2.94 (dd, J=13.2, 6.8 Hz, 2H), 1.88-1.70 (m, 2H), 1.50-1.33 (m, 2H), 1.23 (dt, J=14.4, 7.2 Hz, 3H), 1.01 (t, J=7.2 Hz, 3H), 0.78 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, d-DMSO) δ 11.13 (s, 1H), 8.68 (d, J=8.4 Hz, 1H), 8.11 (d, J=7.2 Hz, 1H), 8.03 (d, J=7.6 Hz, 1H), 7.98-7.87 (m, 1H), 7.74 (t, J=5.6 Hz, 1H), 7.06 (d, J=7.6 Hz, 1H), 2.74 (dd, J=13.2, 6.8 Hz, 2H), 1.35-1.19 (m, 2H), 1.19-0.98 (m, 2H), 0.69 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, d-DMSO) δ 8.69 (d, J=8.4 Hz, 1H), 8.16 (d, J=7.2 Hz, 1H), 8.06 (d, J=7.6 Hz, 1H), 8.03-7.83 (m, 1H), 7.77 (t, J=6.0 Hz, 1H), 7.30 (d, J=7.6 Hz, 1H), 3.72 (d, J=7.2 Hz, 2H), 2.76 (dd, J=12.8, 6.8 Hz, 2H), 2.15 (dt, J=13.2, 6.8 Hz, 1H), 1.37-1.21 (m, 2H), 1.18-1.10 (m, 2H), 0.93 (s, 3H), 0.91 (s, 3H), 0.68 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, d-DMSO) 8.70 (d, J=8.4 Hz, 1H), 8.12 (d, J=7.2 Hz, 1H), 8.08 (d, J=7.6 Hz, 1H), 8.08-7.93 (m, 1H), 7.85 (t, J=6.0 Hz, 1H), 7.30 (d, J=7.6 Hz, 1H), 3.71 (d, J=7.2 Hz, 2H), 2.94 (s, 1H), 2.08-1.96 (m, 1H), 1.47-1.36 (m, 5H), 1.05-0.90 (m, 5H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, d-DMSO) δ 11.10 (s, 1H), 8.69 (d, J=8.4 Hz, 1H), 8.09 (d, J=6.8 Hz, 1H), 8.04 (d, J=7.6 Hz, 1H), 7.96-7.87 (m, 1H), 7.81 (d, J=7.6 Hz, 1H), 7.04 (d, J=7.6 Hz, 1H), 2.93 (s, 1H), 1.58-1.30 (m, 5H), 1.06-0.98 (m, 5H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, d-DMSO) δ 10.82 (s, 1H), 8.70 (d, J=8.4 Hz, 1H), 8.19 (d, J=7.6 Hz, 1H), 8.13 (d, J=6.8 Hz, 1H), 7.95 (t, J=7.6 Hz, 1H), 7.65-7.46 (m, 2H), 7.39-7.24 (m, 3H), 3.88 (q, J=6.8 Hz, 2H), 2.45 (s, 3H), 1.22 (t, J=7.2 Hz, 3H).¹³C NMR (500 MHz, d-DMSO) δ 197.1, 166.6, 143.4, 138.0, 137.5, 133.5, 130.7, 129.6, 128.9, 127.4, 126.0, 125.2, 124.8, 123.9, 123.8, 123.2, 117.7, 103.9, 34.6, 26.5, 13.5.

The synthesis can refer to Example 67.¹H NMR (400 MHz, CDCl₃) δ 8.54 (d, J=8.4 Hz, 1H), 8.09 (d, J=7.6 Hz, 2H), 7.79 (t, J=7.6 Hz, 1H), 7.13 (d, J=8.4 Hz, 2H), 6.94 (d, J=8.4 Hz, 2H), 6.90 (s, 1H), 6.85 (d, J=7.6 Hz, 1H), 3.95 (q, J=7.2 Hz, 2H), 1.36 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, d-DMSO) δ 10.56 (s, 1H), 8.69 (d, J=8.4 Hz, 1H), 8.16-8.11 (m, 2H), 7.93 (t, J=7.6 Hz, 1H), 7.26 (d, J=7.6 Hz, 1H), 7.16 (t, J=7.6 Hz, 2H), 7.04 (d, J=7.6 Hz, 2H), 6.94 (t, J=7.2 Hz, 1H), 3.89 (q, J=7.2 Hz, 2H), 1.23 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, CDCl₃) δ 8.51 (d, J=8.4 Hz, 1H), 8.14 (d, J=7.6 Hz, 1H), 8.07 (d, J=7.2 Hz, 1H), 7.77 (t, J=7.6 Hz, 1H), 7.66 (d, J=8.4 Hz, 1H), 7.22 (t, J=7.6 Hz, 1H), 7.13 (d, J=7.6 Hz, 2H), 6.99 (t, J=7.6 Hz, 1H), 6.84 (d, J=7.6 Hz, 1H), 3.94 (q, J=7.2 Hz, 2H), 1.35 (t, J=7.2 Hz, 3H).

The synthesis can refer to Example 67.¹H NMR (400 MHz, CDCl₃) δ 8.55 (d, J=8.4 Hz, 1H), 8.16 (d, J=7.6 Hz, 1H), 8.10 (d, J=7.2 Hz, 1H), 7.80 (t, J=7.6 Hz, 1H), 7.16-7.01 (m, 3H), 6.93-6.82 (m, 2H), 3.96 (d, J=7.2 Hz, 2H), 1.37 (t, J=7.2 Hz, 3H).

Activity test in vitro: the compounds of the present invention were conducted the AlphaScreen assay to confirm the ability of a ligand to disrupt the interaction of BRD(1) and its SRC1-4 peptide.

1. Purpose of AlphaScreen Assay

To test the ability of the compounds of the present invention inhibit BRD(1) protein.

2. Experimental Materials

BRD4(1) protein, 500 nM; buffer, (10×) MOPS (500 mM), CHAPS (0.5 mM), NaF (500 mM), BSA (1 mg/mL), PH (7.4); streptavidin donor beads 50 μg/mL, nickel acceptor beads 50 μg/mL, BRD4(1) ligand, biotinylated SRC1-4 peptide, H4KAc4-botin (SGRG{Lys-Ac}GG{Lys-Ac}GLG{Lys-Ac}GGA{Lys-Ac} RHR{Lys(biotin)}) 50 nM. 150 μL mix system: BRD4(1) protein, 15 μL; buffer, 15 μL; ddH₂O, 15 μL; compound, 15 μL; streptavidin donor beads, 15 μL; nickel acceptor beads, 15 μL; positive compound, (+)-JQ1.

3. Protocol

The BRD4(1) protein and biotinylated SRC1-4 peptide were added in ddH2O and buffer. The reaction mixture was incubated at 20° C. for 1.5 h, streptavidin donor beads and nickel acceptor beads was added. The reaction mixture was incubated at 20° C. in dark for 1 h. The reaction mixture (40 μL) was transferred to 384 well plates, and tested by PE Envison2104 multifunctional detection of microplate reader. Excitation wavelength, 680 nM; Emission wavelength, 520-620 nM.

Activity test in vitro: the compounds of the present invention were conducted the TSA assay to determine the thermodynamic stability of BRD4(1).

1. Purpose of TSA Assay

To test the ability of the compounds of the present invention inhibit BRD(1) protein.

2. Experimental Materials

BRD4(1) protein, 100 μM; compounds, 400 μM, buffer, (10×) MOPS (50 mM), NaCl (150 mM), glycerin 10%, PH (7.5); Sypro Orange Protein Gel Stain (500×). Mix system: BRD4(1) protein, 2 μL; Sypro Orange Protein Gel Stain (500×), 2 μL; compound, 10 μL; buffer, 2 μL; ddH₂O, 2 μL, positive compound, (+)-JQ1.

3. Protocol

The 10 μL reaction mix was added to 96-well PCR plates. SYPRO Orange (Sigma) was added as a fluorescence probe at a dilution of 1:1000 and incubated with compounds on ice for 30 min. The total DMSO concentration was less than 2%. The TSA was carried out using the Bio-Rad CFX96 Real-Time PCR System. The temperature was raised at a step of 0.5° C. per minute from 30° C. to 80° C. The fluorescence readings were recorded at a 0.5° C. interval, and obtained the ΔTm.

The results come from the AlphaScreen assay and TSA assay in table 1-4.

The compounds of the present invention, especially Examples 1, 2, 3, 4, 5, 8, 9, 10, 17, 18, 19, 20, 21, 30, 31, 78, 97, 99 and 100, showed similar potent when compared (+)-JQ1. The compounds of the present invention were chemically stable and easily prepared when compared positive compound. The use of a compound according to any one of Examples 1-123 in the manufacture of a medicament for the treatment of a disease or a condition for which a BET bromodomain inhibitor is indicated. These data indicated the compounds of the present invention may lead to a new therapeutics to treat cancera, cellar proliferative disorders, inflammatory conditions, autoimmune disorders, sepsis, or viral infections.

The embodiments above described illustrative of several embodiments of the invention, and these illusion are specific and detailed, but not to be construed as limiting the scope of the invention. It should be noted that various modifications and improvements can be made by those skilled in the art without departing from the spirit of the invention, which are within the scope of the present invention. Accordingly, the scope of protection of the present invention should be determined by the appended claims.